

(FILE 'HOME' ENTERED AT 11:51:21 ON 30 MAY 2002)

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH,
USPATFULL, JAPIO' ENTERED AT 11:51:32 ON 30 MAY 2002

L1	56826 S ANTIMICROBIAL ACTIVITY
L2	33736 S ANTIFUNGAL ACTIVITY
L3	102478 S SUBSTANCE P
L4	39 S L1 AND L3
L5	19 S L2 AND L3
L6	39 DUP REM L4 (0 DUPLICATES REMOVED)
L7	19 DUP REM L5 (0 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 11:59:34 ON 30 MAY 2002

=>

L9 ANSWER 1 OF 65 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 ACCESSION NUMBER: 1993:500498 BIOSIS
 DOCUMENT NUMBER: PREV199396124505
 TITLE: Inhibition of murine intestinal inflammation by anti-
substance P antibody.
 AUTHOR(S): Agro, Albert; Stanis, Andrzej M. (1)
 CORPORATE SOURCE: (1) Intestinal Dis. Res. Prog., Dep. Pathol., McMaster
 Univ., 1200 Main St. West, Hamilton, ON L8N 3Z5 Canada
 SOURCE: Regional Immunology, (1993) Vol. 5, No. 2, pp. 120-126.
 ISSN: 0896-0623.
 DOCUMENT TYPE: Article
 LANGUAGE: English

L9 ANSWER 2 OF 65 CABA COPYRIGHT 2002 CABI
 ACCESSION NUMBER: 88:14558 CABA
 DOCUMENT NUMBER: 881340734
 TITLE: Inhibitory effects of levamisole- and
 tetramisole-hydrochloride (in vitro) on Prototheca
 zopfii and **Candida albicans**
 Hemmwirkung von Levamisol- und
 Tetramisolhydrochlorid in vitro gegen Prototheca
 zopfii und **Candida albicans**
 AUTHOR: Bergmann, A.
 CORPORATE SOURCE: Wissenschaftsbereich Microbiologie und Tierseuchen,
 Sektion Tierproduktion und Veterinärmedizin der
 Karl-Marx Universität, Leipzig, German Democratic
 Republic.
 SOURCE: Monatshefte für Veterinärmedizin, (1987) Vol. 42,
 No. 16, pp. 599-602. 7 ref.
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 SUMMARY LANGUAGE: English; Russian

L9 ANSWER 3 OF 65 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1999:216943 CAPLUS
 DOCUMENT NUMBER: 130:236482
 TITLE: Monoclonal antibody to T-cell-derived antigen-binding
 molecule (TABM) and detection of TABM in disease
 states
 INVENTOR(S): Cone, Robert Edward; Georgiou, George Michael; Little,
 Colin Hughes
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 155 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9914243	A1	19990325	WO 1998-AU765	19980916
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9890558	A1	19990405	AU 1998-90558	19980916
PRIORITY APPLN. INFO.:			US 1997-59047P	P 19970916
			AU 1998-5850	A 19980911
			WO 1998-AU765	W 19980916

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 65 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:237581 CAPLUS

DOCUMENT NUMBER: 120:237581

TITLE: Detection of genes by nucleic acid hybridization using capture and reporter probes and optional nucleic acid amplification

INVENTOR(S): Mitsuhashi, Masato; Cooper, Allan

PATENT ASSIGNEE(S): Hitachi Chemical Company Ltd., Japan

SOURCE: PCT Int. Appl., 182 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9402636	A1	19940203	WO 1993-US999	19930129
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 652971	A1	19950517	EP 1993-905793	19930129
R: CH, DE, FR, GB, IT, LI				
JP 07509361	T2	19951019	JP 1993-504409	19930129
US 5580971	A	19961203	US 1995-379081	19950126
US 5639612	A	19970617	US 1995-379078	19950126
PRIORITY APPLN. INFO.:			US 1992-922522	19920728
			US 1992-974406	19921112
			WO 1993-US999	19930129

L9 ANSWER 5 OF 65 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 95024893 EMBASE

DOCUMENT NUMBER: 1995024893

TITLE: High levels of IgA in HIV-1-perinatally-infected children: Antigen specificity and possible role of increased **substance P** plasma levels.

AUTHOR: Rossi M.E.; Resti M.; Azzari C.; Calabri G.; De Martino M.; Galli L.; Carbonella R.; Vierucci A.

CORPORATE SOURCE: Dipartimento di Pediatria, Via Luca Giordano 13,50132 Firenze, Italy

SOURCE: Pediatric Allergy and Immunology, (1994) 5/4 (240-243). ISSN: 0905-6157 CODEN: PALUEE

COUNTRY: Denmark

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 004 Microbiology
007 Pediatrics and Pediatric Surgery
026 Immunology, Serology and Transplantation

LANGUAGE: English

SUMMARY LANGUAGE: English

L9 ANSWER 6 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)

ACCESSION NUMBER: 2002:407170 SCISEARCH

THE GENUINE ARTICLE: 547ZQ

TITLE: Dermal application of jet fuel suppresses secondary immune reactions

AUTHOR: Ramos G; Nghiem D X; Walterscheid J P; Ullrich S E (Reprint)

CORPORATE SOURCE: Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, 1515 Holcombe Blvd, Houston, TX 77030 USA (Reprint); Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77030 USA

COUNTRY OF AUTHOR: USA

SOURCE: TOXICOLOGY AND APPLIED PHARMACOLOGY, (15 APR 2002) Vol. 180, No. 2, pp. 136-144.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.
ISSN: 0041-008X.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 33

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 7 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)

ACCESSION NUMBER: 2001:896861 SCISEARCH

THE GENUINE ARTICLE: 488ZW

TITLE: Induction of histamine release from rat peritoneal mast cells by histatins

AUTHOR: Yoshida M; Kimura T; Kitaichi K; Suzuki R; Baba K; Matsushima M; Tatsumi Y; Shibata E; Takagi K (Reprint); Hasegawa T; Takagi K

CORPORATE SOURCE: Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668560, Japan (Reprint); Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; Aichi Med Sch, Dept Med 3, Sch Med, Aichi 4801195, Japan

COUNTRY OF AUTHOR: Japan

SOURCE: BIOLOGICAL & PHARMACEUTICAL BULLETIN, (NOV 2001) Vol. 24, No. 11, pp. 1267-1270.

Publisher: PHARMACEUTICAL SOC JAPAN, 2-12-15-201 SHIBUYA, SHIBUYA-KU, TOKYO, 150, JAPAN.

ISSN: 0918-6158.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 31

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 8 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)

ACCESSION NUMBER: 97:368347 SCISEARCH

THE GENUINE ARTICLE: WX501

TITLE: Inhibition of human neutrophil functions by sulfated and nonsulfated cholecystokinin octapeptides

AUTHOR: Carrasco M; DelRio M; Hernanz A; DelaFuente M (Reprint)

CORPORATE SOURCE: UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN (Reprint); UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRAS, TAMIL NADU, INDIA

COUNTRY OF AUTHOR: SPAIN; INDIA

SOURCE: PEPTIDES, (APR 1997) Vol. 18, No. 3, pp. 415-422.

Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB.

ISSN: 0196-9781.

DOCUMENT TYPE: Article; Journal

FILE SEGMENT: LIFE

LANGUAGE: English

REFERENCE COUNT: 54

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 9 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)

ACCESSION NUMBER: 93:689339 SCISEARCH

THE GENUINE ARTICLE: MF885

TITLE: STIMULATION BY VASOACTIVE-INTESTINAL-PEPTIDE (VIP) OF PHAGOCYTIC FUNCTION IN RAT MACROPHAGES - PROTEIN-KINASE-C INVOLVEMENT

AUTHOR: DELAFUENTE M (Reprint); DELGADO M; DELRIO M; MARTINEZ C;
 HERNANZ A; GOMARIZ R P
 CORPORATE SOURCE: UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT FISIOL
 ANIM, MADRID 3, SPAIN; UNIV COMPLUTENSE MADRID, FAC
 CIENCIAS BIOL, DEPT BIOL CELULAR, MADRID 3, SPAIN; HOSP LA
 PAZ, SERV BIOQUIM, MADRID, SPAIN
 COUNTRY OF AUTHOR: SPAIN
 SOURCE: REGULATORY PEPTIDES, (03 NOV 1993) Vol. 48, No. 3, pp.
 345-353.
 ISSN: 0167-0115.
 DOCUMENT TYPE: Article; Journal
 FILE SEGMENT: LIFE
 LANGUAGE: ENGLISH
 REFERENCE COUNT: 44
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 10 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
 ACCESSION NUMBER: 93:606596 SCISEARCH
 THE GENUINE ARTICLE: LZ829
 TITLE: STIMULATION OF MURINE PERITONEAL MACROPHAGE FUNCTIONS BY
 NEUROPEPTIDE-Y AND PEPTIDE YY - INVOLVEMENT OF
 PROTEIN-KINASE-C
 AUTHOR: DELAFUENTE M (Reprint); BERNAEZ I; DELRIO M; HERNANZ A
 CORPORATE SOURCE: UNIV COMPLUTENSE, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL
 ANIM 2, E-28040 MADRID, SPAIN (Reprint); HOSP LA PAZ
 INSALUD, SERV BIOQUIM, MADRID, SPAIN
 COUNTRY OF AUTHOR: SPAIN
 SOURCE: IMMUNOLOGY, (OCT 1993) Vol. 80, No. 2, pp. 259-265.
 ISSN: 0019-2805.
 DOCUMENT TYPE: Article; Journal
 FILE SEGMENT: LIFE
 LANGUAGE: ENGLISH
 REFERENCE COUNT: 38
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

=> d bib ab 19 1-10

L9 ANSWER 1 OF 65 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1993:500498 BIOSIS
 DN PREV199396124505
 TI Inhibition of murine intestinal inflammation by anti-**substance**
P antibody.
 AU Agro, Albert; Stanis, Andrzej M. (1)
 CS (1) Intestinal Dis. Res. Prog., Dep. Pathol., McMaster Univ., 1200 Main
 St. West, Hamilton, ON L8N 3Z5 Canada
 SO Regional Immunology, (1993) Vol. 5, No. 2, pp. 120-126.
 ISSN: 0896-0623.
 DT Article
 LA English
 AB Several neuropeptides have recently been shown to affect various aspects
 of the inflammatory process. Among these, the neuropeptide
substance P possesses a host of immune modifying actions,
 which include the enhancement of lymphocyte activity, macrophage function,
 and neutrophil chemotaxis. The role of **substance P**
 during inflamed states has, as yet, not been fully described. Here, in T.
 spiralis-infected mice, we parallel increased levels of **substance**
P both locally, (the gut) and peripherally (serum) with decreased
 lymphocyte responsiveness. Upon the introduction of in vivo antisubstance
P antibody during the infection, levels of **substance P**
 , gastrointestinal inflammation, and lymphocyte proliferation are
 significantly restored to baseline (noninfected) levels. These findings
 suggest that the neuropeptide **substance P** plays an
 important role in promoting inflammation. It also offers the basis for

future pharmacological interventions.

L9 ANSWER 2 OF 65 CABA COPYRIGHT 2002 CABI
AN 88:14558 CABA
DN 881340734
TI Inhibitory effects of levamisole- and tetramisole-hydrochloride (in vitro)
on *Prototheca zopfii* and **Candida albicans**
Hemmwirkung von Levamisol- und Tetramisolhydrochlorid in vitro gegen
Prototheca zopfii und **Candida albicans**
AU Bergmann, A.
CS Wissenschaftsbereich Microbiologie und Tierseuchen, Sektion Tierproduktion
und Veterinarmedizin der Karl-Marx Universität, Leipzig, German Democratic
Republic.
SO Monatshefte für Veterinarmedizin, (1987) Vol. 42, No. 16, pp. 599-602. 7
ref.
DT Journal
LA German
SL English; Russian
AB Agar gel and paper disc diffusion tests were performed on 5 *P. zopfii*
strs. obtained from cases of mastitis and 5 *C. albicans* strs.
obtained from pathological material from various animal species. Levamisol
hydrochloride was clearly shown to be the better of the 2 active
substances. *P. zopfii* proved to be more sensitive than
C. albicans. A comparison of the paper disc diffusion test with
antifungal agents used in human medicine revealed that 4 of 5 *P. zopfii*
strs. were more sensitive to tetramisol hydrochloride. Levamisol
hydrochloride was found to be superior to nystatin in its action against
C. albicans, but less so when compared with amphotericin B.
Miconazole showed no antifungal effect against all *P. zopfii* strs.

L9 ANSWER 3 OF 65 CAPLUS COPYRIGHT 2002 ACS
AN 1999:216943 CAPLUS
DN 130:236482
TI Monoclonal antibody to T-cell-derived antigen-binding molecule (TABM) and
detection of TABM in disease states
IN Cone, Robert Edward; Georgiou, George Michael; Little, Colin Hughes
PA USA
SO PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9914243	A1	19990325	WO 1998-AU765	19980916
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9890558	A1	19990405	AU 1998-90558	19980916
PRAI	US 1997-59047P	P	19970916		
	AU 1998-5850	A	19980911		
	WO 1998-AU765	W	19980916		

AB The present invention relates generally to immunointeractive mols. and their in the detection and/or purifn. of T-cell antigen binding mols. (TABMs). In a specific example, the authors disclose the prepn. and characterization of a monoclonal antibody to TABM. In a second example, transforming growth factor-.beta. is shown to bind TABM and to be activated on TABM binding to its cognate antigen. The ability to det. the presence and levels of particular TABMs may provide useful diagnostic

procedures for a variety of disease conditions.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 65 CAPLUS COPYRIGHT 2002 ACS

AN 1994:237581 CAPLUS

DN 120:237581

TI Detection of genes by nucleic acid hybridization using capture and reporter probes and optional nucleic acid amplification

IN Mitsuhashi, Masato; Cooper, Allan

PA Hitachi Chemical Company Ltd., Japan

SO PCT Int. Appl., 182 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9402636	A1	19940203	WO 1993-US999	19930129
	W: CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 652971	A1	19950517	EP 1993-905793	19930129
	R: CH, DE, FR, GB, IT, LI				
	JP 07509361	T2	19951019	JP 1993-504409	19930129
	US 5580971	A	19961203	US 1995-379081	19950126
	US 5639612	A	19970617	US 1995-379078	19950126
PRAI	US 1992-922522		19920728		
	US 1992-974406		19921112		
	WO 1993-US999		19930129		
AB	A method for detecting the presence of a particular organism, infectious agent, or component of a cell or organism in a biol. sample by nucleic acid hybridization is described. A hybridization probe for the target sequence is immobilized on a solid support, such as microtiter well, and the target sequence is then hybridized to the immobilized probe. A second, labeled probe is then hybridized to this support-polynucleotide structure and binding of this probe is used to quantify the target sequence. Sensitivity of the system may be improved by amplification of the bound or free target polynucleotide. Also included in the present invention are polynucleotide probes and primers and the use of an H-site model and algorithm for the design of these probes and primers with an optimized matching of Tm's based upon related sequences available in data banks.				

L9 ANSWER 5 OF 65 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 95024893 EMBASE

DN 1995024893

TI High levels of IgA in HIV-1-perinatally-infected children: Antigen specificity and possible role of increased **substance P** plasma levels.

AU Rossi M.E.; Resti M.; Azzari C.; Calabri G.; De Martino M.; Galli L.; Carbonella R.; Vierucci A.

CS Dipartimento di Pediatria, Via Luca Giordano 13,50132 Firenze, Italy

SO Pediatric Allergy and Immunology, (1994) 5/4 (240-243).

ISSN: 0905-6157 CODEN: PALUEE

CY Denmark

DT Journal; Article

FS 004 Microbiology

007 Pediatrics and Pediatric Surgery

026 Immunology, Serology and Transplantation

LA English

SL English

AB The specificity of IgA against food, inhalant, bacterial and fungine antigens as well as for HIV-1 proteins was investigated in 14 HIV-1-infected children (CDC stage P-2) and 15 controls. IgA against food-

and inhalant antigens as well as against tetanus toxoid were significantly more often present in the HIV positive children than in controls. No difference between the two groups was present for IgA against **Candida albicans**. A significant increase of **substance P**, a strong IgA synthesis inducing neuropeptide, was demonstrated in the plasma of HIV-1 infected children. In conclusion, high levels of IgA seem to reflect a complex immune dysfunction in which many factors are involved. The importance of neuroimmune dysregulation is discussed.

L9 ANSWER 6 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
AN 2002:407170 SCISEARCH
GA The Genuine Article (R) Number: 547ZQ
TI Dermal application of jet fuel suppresses secondary immune reactions
AU Ramos G; Nghiem D X; Walterscheid J P; Ullrich S E (Reprint)
CS Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, 1515 Holcombe Blvd, Houston, TX 77030 USA (Reprint); Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77030 USA
CYA USA
SO TOXICOLOGY AND APPLIED PHARMACOLOGY, (15 APR 2002) Vol. 180, No. 2, pp. 136-144.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.
ISSN: 0041-008X.
DT Article; Journal
LA English
REC Reference Count: 33
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB Applying military jet fuel (JP-8) to the skin of mice activates systemic immune suppression. In all of our previous experiments, JP-8 was applied to immunologically naive mice. The effect of jet fuels on established immune reactions, such as immunological memory, is unknown. The focus of the experiments presented here was to test the hypothesis that jet fuel exposure [both JP-8 and commercial jet fuel (Jet-A)] suppresses established immune reactions. Mice were immunized with the opportunistic fungal pathogen **Candida albicans** and, at different times after immunization (10 to 30 days), various doses of undiluted JP-8 or Jet-A were applied to their skin. Both the elicitation of delayed-type hypersensitivity (DTH) (mice challenged 10 days after immunization) and immunological memory (mice challenged 30 days after immunization) were significantly suppressed in a dose-dependent manner. Dermal exposure to either multiple small doses (50 μ l over 4 days) or a single large dose (approximate to 200-300 μ l) of JP-8 and/or Jet-A suppressed DTH to **C. albicans**. The mechanism by which dermal application of JP-8 and Jet-A suppresses immunological memory involves the release of immune biologic response modifiers. Blocking the production of prostaglandin E, by a selective cyclooxygenase-2 inhibitor (SC 236) significantly reversed jet fuel-induced suppression of immunologic memory. These findings indicate, for the first time, that dermal exposure to commercial jet fuel (Jet-A) suppresses the immune response. In addition, the data reported here expand on previous findings by suggesting that jet fuel exposure may depress the protective effect of prior vaccination. (C) 2002 Elsevier Science (USA).

L9 ANSWER 7 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
AN 2001:896861 SCISEARCH
GA The Genuine Article (R) Number: 488ZW
TI Induction of histamine release from rat peritoneal mast cells by histatins
AU Yoshida M; Kimura T; Kitaichi K; Suzuki R; Baba K; Matsushima M; Tatsumi Y; Shibata E; Takagi K (Reprint); Hasegawa T; Takagi K
CS Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668560, Japan (Reprint); Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya

Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; Aichi Med Sch, Dept Med 3, Sch Med, Aichi 4801195, Japan

CYA Japan

SO BIOLOGICAL & PHARMACEUTICAL BULLETIN, (NOV 2001) Vol. 24, No. 11, pp. 1267-1270.
 Publisher: PHARMACEUTICAL SOC JAPAN, 2-12-15-201 SHIBUYA, SHIBUYA-KU, TOKYO, 150, JAPAN.
 ISSN: 0918-6158.

DT Article; Journal

LA English

REC Reference Count: 31
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Human salivary histatins (Hsts), which belong to a salivary polypeptide family, have potent antifungal activity against **Candida albicans** and *Cryptococcus neoformans*, and are expected to be useful as therapeutic reagents against **Candida** species. However, little is known about the effect of Hsts on host immune systems. Thus we conducted a series of in vitro experiments with rat mast cells to determine whether histatin 5 (Hst 5) or histatin 8 (Hst 8) has a histamine-releasing effect on mast cells. Both Hst 5 and Hst 8 induced histamine release from rat peritoneal mast cells in a dose-dependent manner (10^{-9} to 10^{-5} M). Hst 5 had a stronger releasing effect than Hst 8. The histamine release induced by Hst 5 (10^{-6} M) was increased by the presence of 0.5 mM Ca^{2+} , but decreased by 2 mM Ca^{2+} . Alternatively, the histamine release induced by Hst 8 (10^{-6} M) was inhibited by the presence of Ca^{2+} (0.5 to 2 mM). These results suggest that Hsts have limited usefulness as therapeutic agents due to induction of histamine release from mast cells.

L9 ANSWER 8 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)

AN 97:368347 SCISEARCH

GA The Genuine Article (R) Number: WX501

TI Inhibition of human neutrophil functions by sulfated and nonsulfated cholecystokinin octapeptides

AU Carrasco M; DelRio M; Hernanz A; DelaFuente M (Reprint)

CS UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN (Reprint); UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRAS, TAMIL NADU, INDIA

CYA SPAIN; INDIA

SO PEPTIDES, (APR 1997) Vol. 18, No. 3, pp. 415-422.
 Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB.
 ISSN: 0196-9781.

DT Article; Journal

FS LIFE

LA English

REC Reference Count: 54
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The effects of CCK-8s and desulfated CCK-8 at concentrations ranging from 10^{-14} to 10^{-6} M were studied in vitro on several functions of human peripheral neutrophils: adherence to substrate, mobility (spontaneous and directed by a chemical gradient or chemotaxis), ingestion of inert particles (latex beads) or cells (**Candida albicans**), and production of superoxide anion measured by the nitroblue tetrazolium reduction test. The effect of CCK-8s on intracellular levels of cAMP was investigated as well as the implication of calcium in the action of CCK-8s on phagocytic function using stimulants and inhibitors of both intracellular and extracellular calcium channels. The two peptides, at concentrations from 10^{-12} to 10^{-8} M, inhibited significantly both mobility and ingestion capacities and increased adherence to substrate. A dose-response relationship was observed with a maximum inhibition of neutrophil functions at 10^{-10} M. CCK-8s and desulfated CCK-8 induced in these cells a significant, but transient,

increase of cAMP levels at 60 s. Moreover, CCK-8s was found to inhibit completely the stimulation of latex bead phagocytosis in neutrophils produced by the calcium ionophore A23187. These results suggest that CCK-8 is a negative modulator of several neutrophil functions and that the inhibition of these activities could be carried out through an increase of the intracellular cAMP levels and a decrease of the extracellular calcium input. (C) 1997 Elsevier Science Inc.

L9 ANSWER 9 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
AN 93:689339 SCISEARCH
GA The Genuine Article (R) Number: MF885
TI STIMULATION BY VASOACTIVE-INTESTINAL-PEPTIDE (VIP) OF PHAGOCYTIC FUNCTION
IN RAT MACROPHAGES - PROTEIN-KINASE-C INVOLVEMENT
AU DELAFUENTE M (Reprint); DELGADO M; DELRIO M; MARTINEZ C; HERNANZ A;
GOMARIZ R P
CS UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT FISIOL ANIM, MADRID 3,
SPAIN; UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL CELULAR,
MADRID 3, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRID, SPAIN
CYA SPAIN
SO REGULATORY PEPTIDES, (03 NOV 1993) Vol. 48, No. 3, pp. 345-353.
ISSN: 0167-0115.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 44
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB The action of vasoactive intestinal peptide (VIP) on macrophages has not yet been studied, although there are studies that show an inhibitory action of VIP on lymphocyte functions. The present study shows that VIP in a range from $10(-12)$ to $10(-7)$ M increased significantly the phagocytosis and digestion capacities of rat peritoneal macrophages. The most effective concentration of VIP was $10(-9)$ M followed by $10(-8)$ M. With respect to the phagocytic capacity, the ingestion of cells (*Candida albicans*) or inert particles (latex beads) was stimulated significantly with all the concentrations used. The digestion capacity was analyzed through the production of superoxide anion, measured by the reduction of nitroblue tetrazolium (NBT). As with phagocytic capacity, superoxide anion production was increased by VIP in non-stimulated macrophages (incubated without latex beads) and even more in stimulated cells (incubated in the presence of latex beads). The study of the mechanism of action of this neuropeptide showed that protein kinase C (PKC) was activated in the presence of VIP concentrations from $10(-10)$ to $10(-8)$ M in a similar way to that found with a specific PKC activator such as phorbol myristate acetate (PMA, 50 ng/ml). PMA also stimulated significantly the phagocytosis and digestion capacities of rat macrophages. By contrast, a PKC inhibitor, retinal (20 μ M), decreased significantly the phagocytosis and digestion capacities. These data show that VIP could stimulate these macrophage functions through PKC activation.

L9 ANSWER 10 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
AN 93:606596 SCISEARCH
GA The Genuine Article (R) Number: LZ829
TI STIMULATION OF MURINE PERITONEAL MACROPHAGE FUNCTIONS BY NEUROPEPTIDE-Y AND PEPTIDE YY - INVOLVEMENT OF PROTEIN-KINASE-C
AU DELAFUENTE M (Reprint); BERNAEZ I; DELRIO M; HERNANZ A
CS UNIV COMPLUTENSE, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, E-28040 MADRID, SPAIN (Reprint); HOSP LA PAZ INSALUD, SERV BIOQUIM, MADRID, SPAIN
CYA SPAIN
SO IMMUNOLOGY, (OCT 1993) Vol. 80, No. 2, pp. 259-265.
ISSN: 0019-2805.
DT Article; Journal
FS LIFE
LA ENGLISH

REC Reference Count: 38

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The peptides neuropeptide Y (NPY) and peptide YY (PYY) at concentrations from 10^{-12} M to 10^{-8} M have been shown in this study to stimulate significantly, in vitro, several functions of resting peritoneal macrophages from BALB/c mice: adherence to substrate, chemotaxis, ingestion of inert particles (latex beads) and foreign cells (*Candida albicans*), and production of superoxide anion measured by nitroblue tetrazolium reduction. A dose-response relationship was observed, with a maximal stimulation of the macrophage functions studied at 10^{-10} M. These effects seem to be produced by specific receptors for the neuropeptides studied in peritoneal macrophages. Whereas the two peptides induced no change of intracellular cyclic AMP, they caused a significant stimulation of protein kinase C (PKC) in murine macrophages. These results suggest that NPY and PYY produce their effects on macrophage function through PKC activation.

=> d his

(FILE 'HOME' ENTERED AT 13:01:06 ON 30 MAY 2002)

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO' ENTERED AT 13:01:31 ON 30 MAY 2002

L1 102478 S SUBSTANCE P
L2 193060 S CANDIDA
L3 167 S L1 AND L2
L4 166 DUP REM L3 (1 DUPLICATE REMOVED)
L5 128 S L4 AND PREVENT?
L6 153 S L4 AND INHIBIT?
L7 3 S L6 AND FUNGAL GROWTH
L8 0 S L4 AND INHIBIT FUNGAL GROWTH
L9 65 S L4 AND ALBICANS

=> dup rem l9

PROCESSING COMPLETED FOR L9

L10 65 DUP REM L9 (0 DUPLICATES REMOVED)

=> d ibib l10 bib ab 1-65

L10 ANSWER 1 OF 65 USPATFULL

ACCESSION NUMBER: 2002:120021 USPATFULL

TITLE: Method for making multispecific antibodies having heteromultimeric and common components

INVENTOR(S): Arathoon, W. Robert, San Mateo, CA, UNITED STATES
Carter, Paul J., San Francisco, CA, UNITED STATES
Merchant, Anne M., San Bruno, CA, UNITED STATES
Presta, Leonard G., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002062010	A1	20020523
APPLICATION INFO.:	US 2001-863693	A1	20010523 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-70166, filed on 30 Apr 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46816P	19970502 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	

NUMBER OF CLAIMS: 29
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 7 Drawing Page(s)
 LINE COUNT: 3173
 AN 2002:120021 USPTFULL
 TI Method for making multispecific antibodies having heteromultimeric and common components
 IN Arathoon, W. Robert, San Mateo, CA, UNITED STATES
 Carter, Paul J., San Francisco, CA, UNITED STATES
 Merchant, Anne M., San Bruno, CA, UNITED STATES
 Presta, Leonard G., San Francisco, CA, UNITED STATES
 PA Genentech, Inc. (U.S. corporation)
 PI US 2002062010 A1 20020523
 AI US 2001-863693 A1 20010523 (9)
 RLI Continuation of Ser. No. US 1998-70166, filed on 30 Apr 1998, PENDING
 PRAI US 1997-46816P 19970502 (60)
 DT Utility
 FS APPLICATION
 LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
 CLMN Number of Claims: 29
 ECL Exemplary Claim: 1
 DRWN 7 Drawing Page(s)
 LN.CNT 3173

AB The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.

L10 ANSWER 2 OF 65 USPTFULL

ACCESSION NUMBER: 2002:106404 USPTFULL
 TITLE: Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology

INVENTOR(S): Cuttitta, Frank, Adamstown, MD, UNITED STATES
 Martinez, Alfredo, McLean, VA, UNITED STATES
 Miller, Mae Jean, Monrovia, MD, UNITED STATES
 Unsworth, Edward J., Kensington, MD, UNITED STATES
 Hook, William, Wheaton, MD, UNITED STATES
 Walsh, Thomas, Bethesda, MD, UNITED STATES
 Gray, Karen, Gaithersburg, MD, UNITED STATES
 Macri, Charles, Kensington, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002055615	A1	20020509
APPLICATION INFO.:	US 2001-931700	A1	20010816 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-11922, filed on 17 Feb 1998, GRANTED, Pat. No. US 6320022		

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: WO 1996-US13286 19960816
US 1995-2514P 19950818 (60)
US 1995-2936P 19950830 (60)
US 1996-13172P 19960312 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN & FINNEGAN, L.L.P., 345 Park Avenue, New York, NY, 10154-0053

NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 2311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:106404 USPTFULL
TI Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
IN Cuttitta, Frank, Adamstown, MD, UNITED STATES
Martinez, Alfredo, McLean, VA, UNITED STATES
Miller, Mae Jean, Monrovia, MD, UNITED STATES
Unsworth, Edward J., Kensington, MD, UNITED STATES
Hook, William, Wheaton, MD, UNITED STATES
Walsh, Thomas, Bethesda, MD, UNITED STATES
Gray, Karen, Gaithersburg, MD, UNITED STATES
Macri, Charles, Kensington, MD, UNITED STATES

PI US 2002055615 A1 20020509
AI US 2001-931700 A1 20010816 (9)
RLI Division of Ser. No. US 1998-11922, filed on 17 Feb 1998, GRANTED, Pat. No. US 6320022

PRAI WO 1996-US13286 19960816
US 1995-2514P 19950818 (60)
US 1995-2936P 19950830 (60)
US 1996-13172P 19960312 (60)

DT Utility
FS APPLICATION
LREP MORGAN & FINNEGAN, L.L.P., 345 Park Avenue, New York, NY, 10154-0053
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 2311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for Tpeptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.

L10 ANSWER 3 OF 65 USPTFULL
ACCESSION NUMBER: 2002:105676 USPTFULL
TITLE: Anti-IgE antibodies
INVENTOR(S): Lowman, Henry B., El Granada, CA, UNITED STATES
Presta, Leonard G., San Francisco, CA, UNITED STATES
Jardieu, Paula M., San Mateo, CA, UNITED STATES
Lowe, John, Daly City, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002054878	A1	20020509
APPLICATION INFO.:	US 2001-920171	A1	20010801 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-296005, filed on 21 Apr 1999, GRANTED, Pat. No. US 6290957 Continuation of Ser. No. US 1997-887352, filed on 2 Jul 1997, GRANTED, Pat. No. US 5994511		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	19 Drawing Page(s)		
LINE COUNT:	5846		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:105676 USPATFULL
 TI Anti-IgE antibodies
 IN Lowman, Henry B., El Granada, CA, UNITED STATES
 Presta, Leonard G., San Francisco, CA, UNITED STATES
 Jardieu, Paula M., San Mateo, CA, UNITED STATES
 Lowe, John, Daly City, CA, UNITED STATES
 PA Genentech, Inc. (U.S. corporation)
 PI US 2002054878 A1 20020509
 AI US 2001-920171 A1 20010801 (9)
 RLI Continuation of Ser. No. US 1999-296005, filed on 21 Apr 1999, GRANTED, Pat. No. US 6290957 Continuation of Ser. No. US 1997-887352, filed on 2 Jul 1997, GRANTED, Pat. No. US 5994511
 DT Utility
 FS APPLICATION
 LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
 CLMN Number of Claims: 31
 ECL Exemplary Claim: 1
 DRWN 19 Drawing Page(s)
 LN.CNT 5846

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

L10 ANSWER 4 OF 65 USPATFULL

ACCESSION NUMBER: 2002:54627 USPATFULL
 TITLE: Characterization of microbial deposition and immune response at the basement membrane and methods relating thereto
 INVENTOR(S): Rosenberg, E. William, Memphis, TN, UNITED STATES
 Noah, Patricia W., Germantown, TN, UNITED STATES
 Skinner, Robert B., JR., Memphis, TN, UNITED STATES
 Mandrell, Timothy D., Memphis, TN, UNITED STATES
 Narula, Jagat, Philadelphia, PA, UNITED STATES
 Handorf, Charles R., Memphis, TN, UNITED STATES

NUMBER	KIND	DATE

PATENT INFORMATION: US 2002031788 A1 20020314
APPLICATION INFO.: US 2001-789102 A1 20010220 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-183647P	20000218 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1173	

CAS INDEXING IS AVAILABLE FOR THIS PATENT..

AN 2002:54627 USPATFULL

TI Characterization of microbial deposition and immune response at the basement membrane and methods relating thereto

IN Rosenberg, E. William, Memphis, TN, UNITED STATES
Noah, Patricia W., Germantown, TN, UNITED STATES
Skinner, Robert B., JR., Memphis, TN, UNITED STATES
Mandrell, Timothy D., Memphis, TN, UNITED STATES
Narula, Jagat, Philadelphia, PA, UNITED STATES
Handorf, Charles R., Memphis, TN, UNITED STATES

PI US 2002031788 A1 20020314

AI US 2001-789102 A1 20010220 (9)

PRAI US 2000-183647P 20000218 (60)

DT Utility

FS APPLICATION

LREP JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707

CLMN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 1173

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for diagnosing a systemic or autoimmune disorder and methods for treating the same by inducing the production of or otherwise providing an autoantibody that recognizes a skin basement membrane component.

L10 ANSWER 5 OF 65 USPATFULL

ACCESSION NUMBER: 2002:32228 USPATFULL

TITLE: Methods for enhancing the expression of a protein of interest by recombinant host cells

INVENTOR(S): Lok, Si, Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019049	A1	20020214
APPLICATION INFO.:	US 2001-842746	A1	20010425 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-199760P	20000426 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Phillip Jones, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA, 98102	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1488	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:32228 USPATFULL

TI Methods for enhancing the expression of a protein of interest by recombinant host cells

IN Lok, Si, Seattle, WA, UNITED STATES
PI US 2002019049 A1 20020214
AI US 2001-842746 A1 20010425 (9)
PRAI US 2000-199760P 20000426 (60)
DT Utility
FS APPLICATION
LREP Phillip Jones, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle,
WA, 98102
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1488

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The increased use of nucleotide sequence data mining techniques has amplified the demand for efficient methods of producing recombinant proteins in eukaryotic cells. A strategy is provided for enhancing the synthesis of recombinant amino acid sequences by polymerizing expression cassettes in vitro before producing recombinant hosts.

L10 ANSWER 6 OF 65 USPATFULL

ACCESSION NUMBER: 2002:12259 USPATFULL
TITLE: Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
INVENTOR(S): Better, Marc D., Los Angeles, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002006638	A1	20020117
APPLICATION INFO.:	US 2001-765527	A1	20010118 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-217352, filed on 21 Dec 1998, GRANTED, Pat. No. US 6274344		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Janet M. McNicholas, Ph. D., McAndrews, Held & Malloy, Ltd., 34th Floor, 500 West Madison Street, Chicago, IL, 60661		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	4350		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:12259 USPATFULL
TI Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
IN Better, Marc D., Los Angeles, CA, UNITED STATES
PI US 2002006638 A1 20020117
AI US 2001-765527 A1 20010118 (9)
RLI Continuation of Ser. No. US 1998-217352, filed on 21 Dec 1998, GRANTED, Pat. No. US 6274344
DT Utility
FS APPLICATION
LREP Janet M. McNicholas, Ph. D., McAndrews, Held & Malloy, Ltd., 34th Floor, 500 West Madison Street, Chicago, IL, 60661
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 4350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).

L10 ANSWER 7 OF 65 USPATFULL

ACCESSION NUMBER: 2002:102627 USPATFULL

TITLE: Sequence directed DNA binding molecules compositions and methods

INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States

PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6384208	B1	20020507
APPLICATION INFO.:	US 1999-354947		19990715 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-482080, filed on 7 Jun 1995, now patented, Pat. No. US 6010849, issued on 4 Jan 2000 Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444, issued on 26 Nov 1996 Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014, issued on 10 Mar 1998 Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463, issued on 2 Dec 1997 Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
ASSISTANT EXAMINER:	Davis, Katharine F.		
LEGAL REPRESENTATIVE:	Fabian, Gary, Thrower, Larry W., Perkins Coie LLP		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	71 Drawing Figure(s); 47 Drawing Page(s)		
LINE COUNT:	5215		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:102627 USPATFULL

TI Sequence directed DNA binding molecules compositions and methods

IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States

PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

PI US 6384208 B1 20020507

AI US 1999-354947 19990715 (9)

RLI Continuation of Ser. No. US 1995-482080, filed on 7 Jun 1995, now patented, Pat. No. US 6010849, issued on 4 Jan 2000 Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444, issued on 26 Nov 1996 Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014, issued on 10 Mar 1998 Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463, issued on 2 Dec 1997 Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Schwartzman, Robert A.; Assistant Examiner: Davis, Katharine F.

LREP Fabian, Gary, Thrower, Larry W., Perkins Coie LLP

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN 71 Drawing Figure(s); 47 Drawing Page(s)

LN.CNT 5215

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 8 OF 65 USPATFULL

ACCESSION NUMBER: 2002:75470 USPATFULL

TITLE: Dithiolane derivatives

INVENTOR(S): Pershadsingh, Harrihar A., Bakersfield, CA, United States

Avery, Mitchell A., Oxford, MS, United States

PATENT ASSIGNEE(S): Bethesda Pharmaceuticals, Inc., Bakersfield, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6369098	B1	20020409
APPLICATION INFO.:	US 2000-684738		20001004 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157890P	19991005 (60)
	US 2000-185347P	20000226 (60)
	US 2000-225907P	20000817 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Lambkin, Deborah C.

LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP

NUMBER OF CLAIMS: 42

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)

LINE COUNT: 3404

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:75470 USPATFULL

TI Dithiolane derivatives

IN Pershadsingh, Harrihar A., Bakersfield, CA, United States

Avery, Mitchell A., Oxford, MS, United States

PA Bethesda Pharmaceuticals, Inc., Bakersfield, CA, United States (U.S. corporation)

PI US 6369098 B1 20020409

AI US 2000-684738 20001004 (9)

PRAI US 1999-157890P 19991005 (60)

US 2000-185347P 20000226 (60)

US 2000-225907P 20000817 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Lambkin, Deborah C.

LREP Townsend and Townsend and Crew LLP

CLMN Number of Claims: 42

ECL Exemplary Claim: 1

DRWN 22 Drawing Figure(s); 22 Drawing Page(s)

LN.CNT 3404

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes methods for synthesizing novel dithiolane derivatives, ligands with high affinity for the nuclear hormone receptors, peroxisome proliferator-activated receptor-.gamma. (PPAR.gamma.) and/or PPAR.alpha.. Methods for using these compounds in the treatment of endocrine, skin, cardiovascular, immunological, neurological, neuropsychiatric, neoplastic and chronic viral diseases of various organs, including the eye are described. Methods of treating proliferative and inflammatory diseases, degenerative diseases, and age-related dysregulations, caused by an hereditary (genetic) condition or an environmental insult are also provided. In addition, methods are provided for treating conditions and diseases comprising the step of administering to a human or an animal in need thereof a therapeutic amount of pharmacological compositions comprising a pharmaceutically acceptable carrier, a PPAR.alpha. agonist, and a second agent selected from the following: a PPAR.gamma. ligand, or an RXR ligand (rexinoid), or a PPAR.gamma./RXR ligand, effective to reverse, slow, stop, or prevent the pathological inflammatory or degenerative process.

L10 ANSWER 9 OF 65 USPATFULL

ACCESSION NUMBER: 2002:63923 USPATFULL
TITLE: Azole compounds, their production and use
INVENTOR(S): Itoh, Katsumi, Osaka, JAPAN
Okonogi, Kenji, Osaka, JAPAN
Tasaka, Akihiro, Osaka, JAPAN
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, JAPAN
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6362206	B1	20020326
APPLICATION INFO.:	US 1999-413876		19991007 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 624649, now patented, Pat. No. US 6034248		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-29579	19950217
	JP 1995-285318	19951101
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Morris, Patricia L.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2251	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:63923 USPATFULL
TI Azole compounds, their production and use
IN Itoh, Katsumi, Osaka, JAPAN
Okonogi, Kenji, Osaka, JAPAN
Tasaka, Akihiro, Osaka, JAPAN
PA Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)
PI US 6362206 B1 20020326
AI US 1999-413876 19991007 (9)
RLI Division of Ser. No. US 624649, now patented, Pat. No. US 6034248
PRAI JP 1995-29579 19950217
JP 1995-285318 19951101
DT Utility
FS GRANTED
EXNAM Primary Examiner: Morris, Patricia L.
LREP Foley & Lardner
CLMN Number of Claims: 11

ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2251

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an azole compound represented by the formula (I): ##STR1##

wherein Ar is an optionally substituted phenyl group; R.sup.1 and R.sup.2, the same or different, are a hydrogen atom or a lower alkyl group, or R.sup.1 and R.sup.2 may combine together to form a lower alkylene group; R is a hydrogen atom or an acyl group; X is a nitrogen atom or a methine group; A is Y.dbd.Z (Y and Z, the same or different, are a nitrogen atom or a methine group optionally substituted with a lower alkyl group) or an ethylene group optionally substituted with a lower alkyl group; n is an integer from 0 to 2; and Az is an optionally substituted azolyl group, or its salt, which is useful for a prevention and therapy of a fungal infection of a mammal as a antifungal agent.

L10 ANSWER 10 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)

ACCESSION NUMBER: 2002:407170 SCISEARCH

THE GENUINE ARTICLE: 547ZQ

TITLE: Dermal application of jet fuel suppresses secondary immune reactions

AUTHOR: Ramos G; Nghiem D X; Walterscheid J P; Ullrich S E (Reprint)

CORPORATE SOURCE: Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, 1515 Holcombe Blvd, Houston, TX 77030 USA (Reprint); Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77030 USA

COUNTRY OF AUTHOR: USA

SOURCE: TOXICOLOGY AND APPLIED PHARMACOLOGY, (15 APR 2002) Vol. 180, No. 2, pp. 136-144.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.
ISSN: 0041-008X.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 33

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 2002:407170 SCISEARCH

GA The Genuine Article (R) Number: 547ZQ

TI Dermal application of jet fuel suppresses secondary immune reactions

AU Ramos G; Nghiem D X; Walterscheid J P; Ullrich S E (Reprint)

CS Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, 1515 Holcombe Blvd, Houston, TX 77030 USA (Reprint); Univ Texas, MD Anderson Canc Ctr, Dept Immunol 178, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77030 USA

CYA USA

SO TOXICOLOGY AND APPLIED PHARMACOLOGY, (15 APR 2002) Vol. 180, No. 2, pp. 136-144.

Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.

ISSN: 0041-008X.

DT Article; Journal

LA English

REC Reference Count: 33

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Applying military jet fuel (JP-8) to the skin of mice activates systemic immune suppression. In all of our previous experiments, JP-8 was applied to immunologically naive mice. The effect of jet fuels on established immune reactions, such as immunological memory, is unknown. The focus of the experiments presented here was to test the hypothesis that jet fuel exposure [both JP-8 and commercial jet fuel (Jet-A)] suppresses established immune reactions. Mice were immunized with the

opportunistic fungal pathogen **Candida albicans** and, at different times after immunization (10 to 30 days), various doses of undiluted JP-8 or Jet-A were applied to their skin. Both the elicitation of delayed-type hypersensitivity (DTH) (mice challenged 10 days after immunization) and immunological memory (mice challenged 30 days after immunization) were significantly suppressed in a dose-dependent manner. Dermal exposure to either multiple small doses (50 mul over 4 days) or a single large dose (approximate to 200-300 mul) of JP-8 and/or Jet-A suppressed DTH to **C. albicans**. The mechanism by which dermal application of JP-8 and Jet-A suppresses immunological memory involves the release of immune biologic response modifiers. Blocking the production of prostaglandin E, by a selective cyclooxygenase-2 inhibitor (SC 236) significantly reversed jet fuel-induced suppression of immunologic memory. These findings indicate, for the first time, that dermal exposure to commercial jet fuel (Jet-A) suppresses the immune response. In addition, the data reported here expand on previous findings by suggesting that jet fuel exposure may depress the protective effect of prior vaccination. (C) 2002 Elsevier Science (USA).

L10 ANSWER 11 OF 65 USPATFULL

ACCESSION NUMBER: 2001:145079 USPATFULL

TITLE: Methods for the isolation of bacteria containing eukaryotic genes

INVENTOR(S): Robinson, Douglas H., Washington, DC, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001018214	A1	20010830
APPLICATION INFO.:	US 2001-759345	A1	20010116 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-382816, filed on 25 Aug 1999, ABANDONED Continuation of Ser. No. US 1996-719367, filed on 25 Sep 1996, GRANTED, Pat. No. US 6022730 Continuation-in-part of Ser. No. US 1994-261977, filed on 17 Jun 1994, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROTHWELL, FIGG, ERNST & MANBECK, P.C., 555 13TH STREET, N.W., SUITE 701, EAST TOWER, WASHINGTON, DC, 20004		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
LINE COUNT:	974		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:145079 USPATFULL

TI Methods for the isolation of bacteria containing eukaryotic genes

IN Robinson, Douglas H., Washington, DC, United States

PI US 2001018214 A1 20010830

AI US 2001-759345 A1 20010116 (9)

RLI Continuation of Ser. No. US 1999-382816, filed on 25 Aug 1999, ABANDONED Continuation of Ser. No. US 1996-719367, filed on 25 Sep 1996, GRANTED, Pat. No. US 6022730 Continuation-in-part of Ser. No. US 1994-261977, filed on 17 Jun 1994, ABANDONED

DT Utility

FS APPLICATION

LREP ROTHWELL, FIGG, ERNST & MANBECK, P.C., 555 13TH STREET, N.W., SUITE 701, EAST TOWER, WASHINGTON, DC, 20004

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 974

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Bacteria containing eukaryotic and/or viral genes, and often having highly pleiomorphic morphology, are obtained by culturing virally-infected eukaryotic cells under aseptic, low oxygen conditions. The bacteria so produced express products encoded by the eukaryotic

genes. Analyses indicate that several isolates obtained from culturing retrovirally-infected human brain capillary endothelial cells express human-specific genes previously mapped to widely separated human chromosomes.

L10 ANSWER 12 OF 65 USPATFULL

ACCESSION NUMBER: 2001:133881 USPATFULL
 TITLE: IMMUNIZATION AGAINST ENDOGENOUS MOLECULES
 INVENTOR(S): HARLAND, RICHARD, SASKATOON, Canada
 MANNS, JOHN G., SASKATOON, Canada
 ACRES, STEPHEN D., SASKATOON, Canada

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014330	A1	20010816
APPLICATION INFO.:	US 1998-19010	A1	19980205 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-36883P	19970205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROBINS & PASTERNAK LLP, 90 MIDDLEFIELD ROAD, SUITE 200, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	1491	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:133881 USPATFULL
 TI IMMUNIZATION AGAINST ENDOGENOUS MOLECULES
 IN HARLAND, RICHARD, SASKATOON, Canada
 MANNS, JOHN G., SASKATOON, Canada
 ACRES, STEPHEN D., SASKATOON, Canada
 PI US 2001014330 A1 20010816
 AI US 1998-19010 A1 19980205 (9)
 PRAI US 1997-36883P 19970205 (60)
 DT Utility
 FS APPLICATION
 LREP ROBINS & PASTERNAK LLP, 90 MIDDLEFIELD ROAD, SUITE 200, MENLO PARK, CA, 94025
 CLMN Number of Claims: 18
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Page(s)
 LN.CNT 1491

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is described for immunoneutralization of endogenous molecules in mammalian subjects, wherein an immunogen is administered via injection to the ear. The method is used to elicit an efficient and uniform immune response sufficient to block or suppress the activity of an endogenous hormone in a vaccinated subject, or to target a diseased cell for an immune response.

L10 ANSWER 13 OF 65 USPATFULL

ACCESSION NUMBER: 2001:235103 USPATFULL
 TITLE: Method and product for regulating cell responsiveness to external signals
 INVENTOR(S): Johnson, Gary L., Boulder, CO, United States
 PATENT ASSIGNEE(S): National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6333170	B1	20011225

APPLICATION INFO.: US 1996-628829 19960405 (8)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-440421, filed on 12 May 1995, now abandoned Continuation-in-part of Ser. No. US 1994-323460, filed on 14 Oct 1994, now patented, Pat. No. US 5854043 Continuation-in-part of Ser. No. US 1993-49254, filed on 15 Apr 1993, now patented, Pat. No. US 5405941, said Ser. No. US 440421 Continuation-in-part of Ser. No. US 1993-49254, filed on 15 Apr 1993, now patented, Pat. No. US 5405941, said Ser. No. US 628829 Continuation-in-part of Ser. No. US 1995-410602, filed on 24 Mar 1995, now abandoned Continuation-in-part of Ser. No. US 1995-472934, filed on 6 Jun 1995, now patented, Pat. No. US 5753446

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Kemmerer, Elizabeth
 ASSISTANT EXAMINER: Basi, Nirmal S.
 LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, DeConti, Jr., Esq., Guilio A., Lauro, Esq., Peter C.

NUMBER OF CLAIMS: 16
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 40 Drawing Figure(s); 30 Drawing Page(s)
 LINE COUNT: 6027
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:235103 USPATFULL
 TI Method and product for regulating cell responsiveness to external signals
 IN Johnson, Gary L., Boulder, CO, United States
 PA National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, United States (U.S. corporation)
 PI US 6333170 B1 20011225
 AI US 1996-628829 19960405 (8)
 RLI Continuation-in-part of Ser. No. US 1995-440421, filed on 12 May 1995, now abandoned Continuation-in-part of Ser. No. US 1994-323460, filed on 14 Oct 1994, now patented, Pat. No. US 5854043 Continuation-in-part of Ser. No. US 1993-49254, filed on 15 Apr 1993, now patented, Pat. No. US 5405941, said Ser. No. US 440421 Continuation-in-part of Ser. No. US 1993-49254, filed on 15 Apr 1993, now patented, Pat. No. US 5405941, said Ser. No. US 628829 Continuation-in-part of Ser. No. US 1995-410602, filed on 24 Mar 1995, now abandoned Continuation-in-part of Ser. No. US 1995-472934, filed on 6 Jun 1995, now patented, Pat. No. US 5753446

DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Kemmerer, Elizabeth; Assistant Examiner: Basi, Nirmal S.
 LREP Lahive & Cockfield, LLP, DeConti, Jr., Esq., Guilio A., Lauro, Esq., Peter C.
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 1
 DRWN 40 Drawing Figure(s); 30 Drawing Page(s)
 LN.CNT 6027
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to isolated MEKK proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to use such proteins to regulate signal transduction in a cell. The present invention also includes therapeutic compositions comprising such proteins or nucleic acid molecules that encode such proteins and their use to treat animals having medical disorders including cancer, inflammation, neurological disorders, autoimmune diseases, allergic reactions, and hormone-related diseases. When MEKK is expressed, it phosphorylates and activates MKKs 1-4 (also referred to as MEK-1, MEK-2 and JNKK1 and JNKK2).

L10 ANSWER 14 OF 65 USPATFULL

ACCESSION NUMBER: 2001:231160 USPATFULL
TITLE: Secreted salivary ZSIG63 Polypeptide
INVENTOR(S): Adler, David A., Bainbridge Island, WA, United States
Sheppard, Paul O., Granite Falls, WA, United States
PATENT ASSIGNEE(S): ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6331413	B1	20011218
APPLICATION INFO.:	US 2000-527345		20000317 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124820P	19990317 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Prouty, Rebecca E.	
ASSISTANT EXAMINER:	Monshipouri, Maryam	
LEGAL REPRESENTATIVE:	Johnson, JD, Jennifer K.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2896	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:231160 USPATFULL
TI Secreted salivary ZSIG63 Polypeptide
IN Adler, David A., Bainbridge Island, WA, United States
Sheppard, Paul O., Granite Falls, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6331413 B1 20011218
AI US 2000-527345 20000317 (9)
PRAI US 1999-124820P 19990317 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Monshipouri, Maryam
LREP Johnson, JD, Jennifer K.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2896

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to polynucleotide and polypeptide molecules for zsig63, a novel secreted salivary protein. The polypeptides, and polynucleotides encoding them, may exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The polynucleotides encoding zsig63, are located on chromosome 4, and can be used to identify a region of the genome associated with human disease states. The present invention also includes antibodies to the zsig63 polypeptides.

L10 ANSWER 15 OF 65 USPATFULL

ACCESSION NUMBER: 2001:208983 USPATFULL
TITLE: Adrenomedullin peptides
INVENTOR(S): Cutitta, Frank, Adamstown, MD, United States
Martinez, Alfredo, Washington, DC, United States
Miller, Mae Jean, Monrovia, MD, United States
Unsworth, Edward J., Kensington, MD, United States
Hook, William, Wheaton, MD, United States
Walsh, Thomas, Bethesda, MD, United States
Gray, Karen, Gaithersburg, MD, United States
Macri, Charles, Kensington, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the

Department of Health and Human Services, Washington,
DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6320022	B1	20011120
	WO 9707214		19970227
APPLICATION INFO.:	US 1998-11922		19980217 (9)
	WO 1996-US13286		19960816
			19980217 PCT 371 date
			19980217 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-13172P	19960312 (60)
	US 1995-2936P	19950830 (60)
	US 1995-2514P	19950818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Ungar, Susan	
LEGAL REPRESENTATIVE:	Morgan & Finnegan, LLP	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	76 Drawing Figure(s); 26 Drawing Page(s)	
LINE COUNT:	2185	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:208983 USPTFULL

TI Adrenomedullin peptides

IN Cutitta, Frank, Adamstown, MD, United States
Martinez, Alfredo, Washington, DC, United States
Miller, Mae Jean, Monrovia, MD, United States
Unsworth, Edward J., Kensington, MD, United States
Hook, William, Wheaton, MD, United States
Walsh, Thomas, Bethesda, MD, United States
Gray, Karen, Gaithersburg, MD, United States
Macri, Charles, Kensington, MD, United States

PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

PI US 6320022 B1 20011120
WO 9707214 19970227

AI US 1998-11922 19980217 (9)
WO 1996-US13286 19960816
19980217 PCT 371 date
19980217 PCT 102(e) date

PRAI US 1996-13172P 19960312 (60)
US 1995-2936P 19950830 (60)
US 1995-2514P 19950818 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Ungar, Susan

LREP Morgan & Finnegan, LLP

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 76 Drawing Figure(s); 26 Drawing Page(s)

LN.CNT 2185

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The

methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.

L10 . ANSWER 16 OF 65 USPATFULL

ACCESSION NUMBER: 2001:157795 USPATFULL

TITLE: Anti-IgE antibodies and method of improving polypeptides

INVENTOR(S): Lowman, Henry B., 400 San Juan Ave., El Granada, CA, United States 94018
 Presta, Leonard G., 1900 Gough St. #206, San Francisco, CA, United States 94109
 Jardieu, Paula M., 33 Hayward Ave. #110, San Mateo, CA, United States 94401-4319
 Lowe, John, 396 Michelle La., Daly City, CA, United States 94080

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6290957	B1	20010918
APPLICATION INFO.:	US 1999-296005		19990421 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-887352, filed on 2 Jul 1997, now patented, Pat. No. US 5994511		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Saunders, David		
LEGAL REPRESENTATIVE:	Svoboda, Craig G.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 19 Drawing Page(s)		
LINE COUNT:	4910		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:157795 USPATFULL

TI Anti-IgE antibodies and method of improving polypeptides

IN Lowman, Henry B., 400 San Juan Ave., El Granada, CA, United States 94018

Presta, Leonard G., 1900 Gough St. #206, San Francisco, CA, United States 94109

Jardieu, Paula M., 33 Hayward Ave. #110, San Mateo, CA, United States 94401-4319

Lowe, John, 396 Michelle La., Daly City, CA, United States 94080

PI US 6290957 B1 20010918

AI US 1999-296005 19990421 (9)

RLI Continuation of Ser. No. US 1997-887352, filed on 2 Jul 1997, now patented, Pat. No. US 5994511

DT Utility

FS GRANTED

EXNAM Primary Examiner: Saunders, David

LREP Svoboda, Craig G.

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 21 Drawing Figure(s); 19 Drawing Page(s)

LN.CNT 4910

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues

is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

L10 ANSWER 17 OF 65 USPATFULL

ACCESSION NUMBER: 2001:131064 USPATFULL
 TITLE: Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
 INVENTOR(S): Better, Marc D., Los Angeles, CA, United States
 PATENT ASSIGNEE(S): XOMA Corporation, Berkeley, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6274344	B1	20010814
APPLICATION INFO.:	US 1998-217352		19981221 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-621803, filed on 22 Mar 1996, now patented, Pat. No. US 5851802		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Carlson, Karen Cochrane		
ASSISTANT EXAMINER:	Robinson, Patricia		
LEGAL REPRESENTATIVE:	McAndrews, Held & Malloy, Ltd.		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	1612		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:131064 USPATFULL
 TI Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
 IN Better, Marc D., Los Angeles, CA, United States
 PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
 PI US 6274344 B1 20010814
 AI US 1998-217352 19981221 (9)
 RLI Continuation of Ser. No. US 1996-621803, filed on 22 Mar 1996, now patented, Pat. No. US 5851802
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Robinson, Patricia
 LREP McAndrews, Held & Malloy, Ltd.
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 1
 DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
 LN.CNT 1612

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).

L10 ANSWER 18 OF 65 USPATFULL

ACCESSION NUMBER: 2001:125966 USPATFULL
 TITLE: Reduction of impairment of respiratory tract mucosal immunity
 INVENTOR(S): Kudsk, Kenneth A., Memphis, TN, United States
 PATENT ASSIGNEE(S): University of Tennessee Research Corporation, Knoxville, TN, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6271202 B1 20010807
APPLICATION INFO.: US 1998-67032 19980428 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-842877, filed
on 17 Apr 1997, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-15835P	19960419 (60)
	US 1996-29689P	19961031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Davenport, Avis M.	
LEGAL REPRESENTATIVE:	Morgan, Lewis & Bockius LLP	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	1498	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:125966 USPATFULL
TI Reduction of impairment of respiratory tract mucosal immunity
IN Kudsk, Kenneth A., Memphis, TN, United States
PA University of Tennessee Research Corporation, Knoxville, TN, United
States (U.S. corporation)
PI US 6271202 B1 20010807
AI US 1998-67032 19980428 (9)
RLI Continuation-in-part of Ser. No. US 1997-842877, filed on 17 Apr 1997,
now abandoned
PRAI US 1996-15835P 19960419 (60)
US 1996-29689P 19961031 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Davenport, Avis M.
LREP Morgan, Lewis & Bockius LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1498

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes methods for reducing the impairment
respiratory tract mucosal immunity associated with a lack of enteral
feeding or a lack of immunological stimulation of the gastrointestinal
tract comprising administering a therapeutically effective amount of a
neuropeptide. Also described are methods for reducing the rate of
infection of the respiratory tract by pathogenic microorganisms
associated with a lack of enteral feeding or a lack of immunological
stimulation of the gastrointestinal tract comprising administering a
therapeutically effective amount of a neuropeptide. In addition, a
method of reducing the atrophy or dysfunction of the GALT comprising
administering a therapeutically effective amount of a neuropeptide is
described. The specification further describes compositions for reducing
or preventing the impairment of intestinal or respiratory tract mucosal
immunity comprising a neuropeptide and a pharmaceutically acceptable
carrier.

L10 ANSWER 19 OF 65 USPATFULL

ACCESSION NUMBER: 2001:112293 USPATFULL

TITLE: Reduction of impairment of respiratory tract mucosal
immunity

INVENTOR(S): Kudsk, Kenneth A., Memphis, TN, United States

PATENT ASSIGNEE(S): University of Tennessee Research Corporation, Memphis,
TN, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6262027 B1 20010717
APPLICATION INFO.: US 1999-473355 19991228 (9)
RELATED APPLN. INFO.: Division of Ser. No. US 1998-67032, filed on 28 Apr
1998 Continuation-in-part of Ser. No. US 1997-842877,
filed on 17 Apr 1997, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-15835P	19960419 (60)
	US 1996-29689P	19961031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Davenport, Avis M.	
LEGAL REPRESENTATIVE:	Morgan, Lewis & Bockius LLP	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1489	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:112293 USPATFULL
TI Reduction of impairment of respiratory tract mucosal immunity
IN Kudsk, Kenneth A., Memphis, TN, United States
PA University of Tennessee Research Corporation, Memphis, TN, United States
(U.S. corporation)
PI US 6262027 B1 20010717
AI US 1999-473355 19991228 (9)
RLI Division of Ser. No. US 1998-67032, filed on 28 Apr 1998
Continuation-in-part of Ser. No. US 1997-842877, filed on 17 Apr 1997,
now abandoned
PRAI US 1996-15835P 19960419 (60)
US 1996-29689P 19961031 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Davenport, Avis M.
LREP Morgan, Lewis & Bockius LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1489

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes methods for reducing the impairment
respiratory tract mucosal immunity associated with a lack of enteral
feeding or a lack of immunological stimulation of the gastrointestinal
tract comprising administering a therapeutically effective amount of a
neuropeptide. Also described are methods for reducing the rate of
infection of the respiratory tract by pathogenic microorganisms
associated with a lack of enteral feeding or a lack of immunological
stimulation of the gastrointestinal tract comprising administering a
therapeutically effective amount of a neuropeptide. In addition, a
method of reducing the atrophy or dysfunction of the GALT comprising
administering a therapeutically effective amount of a neuropeptide is
described. The specification further describes compositions for reducing
or preventing the impairment of intestinal or respiratory tract mucosal
immunity comprising a neuropeptide and a pharmaceutically acceptable
carrier.

L10 ANSWER 20 OF 65 USPATFULL

ACCESSION NUMBER: 2001:82521 USPATFULL

TITLE: Methods for determining binding of an analyte to a
receptor

INVENTOR(S): Idusogie, Esohe Ekinaduese, Burlingame, CA, United
States
Mulkerrin, Michael George, Hillsborough, CA, United
States

PATENT ASSIGNEE(S):

Presta, Leonard G., San Francisco, CA, United States
Shields, Robert Laird, San Mateo, CA, United States
Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6242195	B1	20010605
APPLICATION INFO.:	US 1998-54255		19980402 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Brumback, Brenda		
ASSISTANT EXAMINER:	Nichols, Jennifer		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	2588		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:82521 USPATFULL
TI Methods for determining binding of an analyte to a receptor
IN Idusogie, Esohe Ekinaduese, Burlingame, CA, United States
Mulkerrin, Michael George, Hillsborough, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Shields, Robert Laird, San Mateo, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6242195 B1 20010605
AI US 1998-54255 19980402 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Brumback, Brenda; Assistant Examiner: Nichols,
Jennifer
LREP Lee, Wendy M.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2588

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, Clq binding and/or complement dependent cytotoxicity (CDC) activity may be reduced or abolished in the variant polypeptide. The application also describes an immune complex and an assay for determining binding of an analyte, such as an Fc region-containing polypeptide, to a receptor.

L10 ANSWER 21 OF 65 USPATFULL

ACCESSION NUMBER: 2001:29701 USPATFULL
TITLE: Polypeptide variants
INVENTOR(S): Idusogie, Esohe Ekinaduese, Burlingame, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Mulkerrin, Michael George, Hillsborough, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6194551	B1	20010227
APPLICATION INFO.:	US 1999-282505		19990331 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-80447P	19980402 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chan, Christina Y.	
ASSISTANT EXAMINER:	DiBrino, Marianne	
LEGAL REPRESENTATIVE:	Lee, Wendy M.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	2593	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AN	2001:29701	USPATFULL
TI	Polypeptide variants	
IN	Idusogie, Esohe Ekinaduese, Burlingame, CA, United States	
	Presta, Leonard G., San Francisco, CA, United States	
	Mulkerrin, Michael George, Hillsborough, CA, United States	
PA	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)	
PI	US 6194551	B1 20010227
AI	US 1999-282505	19990331 (9)
PRAI	US 1998-80447P	19980402 (60)
DT	Utility	
FS	Granted	
EXNAM	Primary Examiner: Chan, Christina Y.; Assistant Examiner: DiBrino, Marianne	
LREP	Lee, Wendy M.	
CLMN	Number of Claims: 9	
ECL	Exemplary Claim: 1	
DRWN	6 Drawing Figure(s); 5 Drawing Page(s)	
LN.CNT	2593	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be reduced or abolished in the variant polypeptide. The application also describes an immune complex and an assay for determining binding of an analyte, such as an Fc region-containing polypeptide, to a receptor.	

L10 ANSWER 22 OF 65 USPATFULL

ACCESSION NUMBER: 2001:14522 USPATFULL

TITLE: Esters of acyl L-carnitines and pharmaceutical compositions containing same for treating endotoxic shock

INVENTOR(S): Foresta, Piero, Pomezia, Italy
Ruggiero, Vito, Rome, Italy
Tinti, Maria Ornella, Rome, Italy
Scafetta, Nazareno, Pavona di Albano, Italy

PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Rome, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6180667	B1	20010130
APPLICATION INFO.:	US 1997-827448		19970328 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-274686, filed on 14 Jul 1994, now patented, Pat. No. US 5625085		

NUMBER	DATE
--------	------

PRIORITY INFORMATION: IT 1993-RM468 19930714
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Shippen, Michael L.
 LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
 NUMBER OF CLAIMS: 8
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 14 Drawing Figure(s); 14 Drawing Page(s)
 LINE COUNT: 967
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AN 2001:14522 USPATFULL
 TI Esters of acyl L-carnitines and pharmaceutical compositions containing
 same for treating endotoxic shock
 IN Foresta, Piero, Pomezia, Italy
 Ruggiero, Vito, Rome, Italy
 Tinti, Maria Ornella, Rome, Italy
 Scafetta, Nazareno, Pavona di Albano, Italy
 PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Rome, Italy (non-U.S.
 corporation)
 PI US 6180667 B1 20010130
 AI US 1997-827448 19970328 (8)
 RLI Division of Ser. No. US 1994-274686, filed on 14 Jul 1994, now patented,
 Pat. No. US 5625085
 PRAI IT 1993-RM468 19930714
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Shippen, Michael L.
 LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
 CLMN Number of Claims: 8
 ECL Exemplary Claim: 1
 DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
 LN.CNT 967

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters of alkanoyl L-carnitines wherein the alkanoyl is a saturated or
 unsaturated, straight or branched alkanoyl having 2-26 carbon atoms,
 optionally .omega.-substituted with trialkylammonium, dialkylsulfonium,
 hydroxyl, carboxyl, halogen, methanesulfonyl and hydroxysulfonyl, are
 useful for preparing pharmaceutical compositions for the treatment of
 endotoxic shock.

L10 ANSWER 23 OF 65 USPATFULL

ACCESSION NUMBER: 2001:4887 USPATFULL
 TITLE: Anti-IgE antibodies and method of improving
 polypeptides
 INVENTOR(S): Lowman, Henry B., El Granada, CA, United States
 Presta, Leonard G., San Francisco, CA, United States
 Jardieu, Paula M., San Mateo, CA, United States
 Lowe, John, Daly City, CA, United States
 PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6172213	B1	20010109
APPLICATION INFO.:	US 1998-109207		19980630 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-51554P	19970702 (60)
DOCUMENT TYPE:	Patent	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chan, Christina Y.	
ASSISTANT EXAMINER:	Ewoldt, Gerald R.	

LEGAL REPRESENTATIVE: Svoboda, Craig G.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 4829

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:4887 USPATFULL
TI Anti-IgE antibodies and method of improving polypeptides
IN Lowman, Henry B., El Granada, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Jardieu, Paula M., San Mateo, CA, United States
Lowe, John, Daly City, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6172213 B1 20010109
AI US 1998-109207 19980630 (9)
PRAI US 1997-51554P 19970702 (60)
DT Patent
FS Granted
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Ewoldt, Gerald
R.
LREP Svoboda, Craig G.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 4829

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for adjusting the affinity of
a polypeptide to a target molecule by a combination of steps, including:
(1) the identification of aspartyl residues which are prone to
isomerization; (2) the substitution of alternative residues and
screening the resulting mutants for affinity against the target
molecule. In a preferred embodiment, the method of substituting residues
is affinity maturation with phage display (AMPD). In a further preferred
embodiment the polypeptide is an antibody and the target molecule is an
antigen. In a further preferred embodiment, the antibody is anti-IgE and
the target molecule is IgE. In another embodiment, the invention relates
to an anti-IgE antibody having improved affinity to IgE.

L10 ANSWER 24 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)

ACCESSION NUMBER: 2001:896861 SCISEARCH

THE GENUINE ARTICLE: 4882W

TITLE: Induction of histamine release from rat peritoneal mast
cells by histatins

AUTHOR: Yoshida M; Kimura T; Kitaichi K; Suzuki R; Baba K;
Matsushima M; Tatsumi Y; Shibata E; Takagi K (Reprint);
Hasegawa T; Takagi K

CORPORATE SOURCE: Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa
Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668560, Japan
(Reprint); Nagoya Univ, Sch Med, Dept Internal Med & Lab
Med 2, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya
Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya,
Aichi 4618673, Japan; Aichi Med Sch, Dept Med 3, Sch Med,
Aichi 4801195, Japan

COUNTRY OF AUTHOR: Japan

SOURCE: BIOLOGICAL & PHARMACEUTICAL BULLETIN, (NOV 2001) Vol. 24,
No. 11, pp. 1267-1270.

Publisher: PHARMACEUTICAL SOC JAPAN, 2-12-15-201 SHIBUYA,
SHIBUYA-KU, TOKYO, 150, JAPAN.

ISSN: 0918-6158.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 31

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 2001:896861 SCISEARCH
GA The Genuine Article (R) Number: 488ZW
TI Induction of histamine release from rat peritoneal mast cells by histatins
AU Yoshida M; Kimura T; Kitaichi K; Suzuki R; Baba K; Matsushima M; Tatsumi Y; Shibata E; Takagi K (Reprint); Hasegawa T; Takagi K
CS Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668560, Japan (Reprint); Nagoya Univ, Sch Med, Dept Internal Med & Lab Med 2, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; Aichi Med Sch, Dept Med 3, Sch Med, Aichi 4801195, Japan
CYA Japan
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN, (NOV 2001) Vol. 24, No. 11, pp. 1267-1270.
Publisher: PHARMACEUTICAL SOC JAPAN, 2-12-15-201 SHIBUYA, SHIBUYA-KU, TOKYO, 150, JAPAN.
ISSN: 0918-6158.
DT Article; Journal
LA English
REC Reference Count: 31

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Human salivary histatins (Hsts), which belong to a salivary polypeptide family, have potent antifungal activity against **Candida albicans** and **Cryptococcus neoformans**, and are expected to be useful as therapeutic reagents against **Candida** species. However, little is known about the effect of Hsts on host immune systems. Thus we conducted a series of in vitro experiments with rat mast cells to determine whether histatin 5 (Hst 5) or histatin 8 (Hst 8) has a histamine-releasing effect on mast cells. Both Hst 5 and Hst 8 induced histamine release from rat peritoneal mast cells in a dose-dependent manner (10^{-9} to 10^{-5} M). Hst 5 had a stronger releasing effect than Hst 8. The histamine release induced by Hst 5 (10^{-6} M) was increased by the presence of 0.5 mM Ca^{2+} , but decreased by 2 mM Ca^{2+} . Alternatively, the histamine release induced by Hst 8 (10^{-6} M) was inhibited by the presence of Ca^{2+} (0.5 to 2 mM). These results suggest that Hsts have limited usefulness as therapeutic agents due to induction of histamine release from mast cells.

L10 ANSWER 25 OF 65 USPATFULL

ACCESSION NUMBER: 2000:160615 USPATFULL
TITLE: Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
INVENTOR(S): Jin, Tuo, Newark, NJ, United States
Zarif, Leila, Newark, NJ, United States
Mannino, Raphael, Annandale, NJ, United States
PATENT ASSIGNEE(S): Biodelivery Sciences, Inc., Newark, NJ, United States (U.S. corporation)
University of Medicine and Denistry of New Jersey, Newark, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6153217		20001128
APPLICATION INFO.:	US 1999-235400		19990122 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kishore, Gollamudi S.		
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas, PLLC		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	651		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:160615 USPATFULL

TI Nanocochleate formulations, process of preparation and method of

delivery of pharmaceutical agents
IN Jin, Tuo, Newark, NJ, United States
Zarif, Leila, Newark, NJ, United States
Mannino, Raphael, Annandale, NJ, United States
PA Biodelivery Sciences, Inc., Newark, NJ, United States (U.S. corporation)
University of Medicine and Denistry of New Jersey, Newark, NJ, United
States (U.S. corporation)
PI US 6153217 20001128
AI US 1999-235400 19990122 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Kishore, Gollamudi S.
LREP Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 651

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for producing a small-sized, lipid-based cochleate is described. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structure by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca.sup.2+ or Zn.sup.2+, forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing pharmaceutical agents or biologically relevant molecules. Small-sized cochleates may be administered orally or through the mucosa to obtain an effective method of treatment.

L10 ANSWER 26 OF 65 USPATFULL

ACCESSION NUMBER: 2000:121617 USPATFULL
TITLE: Libraries of backbone-cyclized peptidomimetics
INVENTOR(S): Gilon, Chaim, Jerusalem, Israel
Hornik, Vered, Rehovot, Israel
PATENT ASSIGNEE(S): Peptor Limited, Rehovot, Israel (non-U.S. corporation)
Yisum Research Development Company of The Hebrew
University in Jerusalem, Jerusalem, Israel (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117974		20000912
APPLICATION INFO.:	US 1995-569042		19951207 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-444135, filed on 18 May 1995, now patented, Pat. No. US 5723575 which is a continuation-in-part of Ser. No. US 1992-955380, filed on 1 Oct 1992, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1991-99628	19911002
	IL 1995-115096	19950829
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Celsa, Bennett	
ASSISTANT EXAMINER:	Ricigliamo, Joseph W.	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2150	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:121617 USPATFULL
TI Libraries of backbone-cyclized peptidomimetics

IN Gilon, Chaim, Jerusalem, Israel
 Hornik, Vered, Rehovot, Israel
 PA Peptor Limited, Rehovot, Israel (non-U.S. corporation)
 Yisum Research Development Company of The Hebrew University in
 Jerusalem, Jerusalem, Israel (non-U.S. corporation)
 PI US 6117974 20000912
 AI US 1995-569042 19951207 (8)
 RLI Continuation-in-part of Ser. No. US 1995-444135, filed on 18 May 1995,
 now patented, Pat. No. US 5723575 which is a continuation-in-part of
 Ser. No. US 1992-955380, filed on 1 Oct 1992, now abandoned
 PRAI IL 1991-99628 19911002
 IL 1995-115096 19950829
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Celsa, Bennett; Assistant Examiner: Ricigliamo, Joseph
 W.
 LREP Pennie & Edmonds LLP
 CLMN Number of Claims: 24
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2150

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Libraries of novel backbone-cyclized peptide analogs are formed by means
 of bridging groups attached via the alpha nitrogens of amino acid
 derivatives to provide novel non-peptidic linkages. Novel building units
 used in the synthesis of these backbone-cyclized peptide analogs are
 N((-functionalized) amino acids constructed to include a spacer and a
 terminal functional group. One or more of these N((-functionalized)
 amino acids are incorporated into a library of peptide sequences,
 preferably during solid phase peptide synthesis. The reactive terminal
 functional groups are protected by specific protecting groups that can
 be selectively removed to effect either backbone-to-backbone or
 backbone-to-side chain cyclizations. The invention is exemplified by
 libraries of backbone-cyclized bradykinin analogs, somatostatin analogs,
 BPI analogs and **Substance P** analogs having
 biological activity. Further embodiments of the invention are
 Interleukin-6 receptor derived peptides having ring structures involving
 backbone cyclization.

L10 ANSWER 27 OF 65 USPATFULL

ACCESSION NUMBER: 2000:117288 USPATFULL
 TITLE: Pharmaceutical grade St. John's Wort
 INVENTOR(S): Khwaja, Tasneem A., Corona Del Mar, CA, United States
 Friedman, Elliot P., Montecito, CA, United States
 PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA,
 United States (U.S. corporation)
 Pharmaprint Inc., Irvine, CA, United States (U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6113907		20000905
APPLICATION INFO.:	US 1997-956602		19971023 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-838198, filed on 15 Apr 1997, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Gitomer, Ralph		
LEGAL REPRESENTATIVE:	Lyon & Lyon LLP		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	3067		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:117288 USPATFULL
TI Pharmaceutical grade St. John's Wort
IN Khwaja, Tasneem A., Corona Del Mar, CA, United States
Friedman, Elliot P., Montecito, CA, United States
PA University of Southern California, Los Angeles, CA, United States (U.S. corporation)
Pharmaprint Inc., Irvine, CA, United States (U.S. corporation)
PI US 6113907 20000905
AI US 1997-956602 19971023 (8)
RLI Continuation-in-part of Ser. No. US 1997-838198, filed on 15 Apr 1997, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Gitomer, Ralph
LREP Lyon & Lyon LLP
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 3067

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to St. John's Wort materials and methods for making such materials in medicinally useful and pharmaceutically acceptable forms. More particularly, the present invention relates to the use of compositional and activity fingerprints in the processing of St. John's Wort materials to produce drugs which qualify as pharmaceutical grade compositions which are suitable for use in clinical or veterinary settings to treat and/or ameliorate diseases, disorders or conditions.

L10 ANSWER 28 OF 65 USPATFULL

ACCESSION NUMBER: 2000:98190 USPATFULL
TITLE: Noncloning technique for expressing a gene of interest
INVENTOR(S): Selby, Mark, San Francisco, CA, United States
Thudium, Kent B., Oakland, CA, United States
Dina, Dino, Oakland, CA, United States
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6096505		20000801
APPLICATION INFO.:	US 1999-290449		19990413 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-81777P	19980414 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Schwartzman, Robert A.	
ASSISTANT EXAMINER:	Sandals, William	
LEGAL REPRESENTATIVE:	Robins, Roberta L., Harbin, Alisa A., Blackburn, Robert P.	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	1328	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:98190 USPATFULL
TI Noncloning technique for expressing a gene of interest
IN Selby, Mark, San Francisco, CA, United States
Thudium, Kent B., Oakland, CA, United States
Dina, Dino, Oakland, CA, United States
PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 6096505 20000801

AI US 1999-290449 19990413 (9)
 PRAI US 1998-81777P 19980414 (60)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Schwartzman, Robert A.; Assistant Examiner: Sandals, William
 LREP Robins, Roberta L., Harbin, Alisa A., Blackburn, Robert P.
 CLMN Number of Claims: 36
 ECL Exemplary Claim: 1
 DRWN 7 Drawing Figure(s); 6 Drawing Page(s)
 LN.CNT 1328

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A noncloning method for expressing a gene of interest in a mammalian host cell is disclosed. The invention utilizes three basic individual elements: (1) a promoter element; (2) at least one gene of interest; and (3) a selectable marker cassette which includes in 5' to 3' order, an internal ribosome entry site ("IRES"), at least one gene coding for a selectable marker, and a transcription termination sequence. The three individual elements are cotransfected into a mammalian host cell where they become operably linked such that expression of the selectable marker gene(s) necessarily requires coexpression of the gene of interest.

L10 ANSWER 29 OF 65 USPATFULL

ACCESSION NUMBER: 2000:41003 USPATFULL
 TITLE: Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
 INVENTOR(S): Ariizumi, Kiyoshi, Dallas, TX, United States
 Takashima, Akira, Irving, TX, United States
 PATENT ASSIGNEE(S): Board of Regents The University of Texas Systems, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6046158		20000404
APPLICATION INFO.:	US 1996-772440		19961220 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Johnson, Nancy A		
LEGAL REPRESENTATIVE:	Arnold White & Durkee		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1,2		
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	6533		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:41003 USPATFULL
 TI Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
 IN Ariizumi, Kiyoshi, Dallas, TX, United States
 Takashima, Akira, Irving, TX, United States
 PA Board of Regents The University of Texas Systems, Austin, TX, United States (U.S. corporation)
 PI US 6046158 20000404
 AI US 1996-772440 19961220 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Johnson, Nancy A
 LREP Arnold White & Durkee
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 1,2
 DRWN 17 Drawing Figure(s); 13 Drawing Page(s)
 LN.CNT 6533

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel genes expressed selectively by long-term dendritic cell (DC) lines

(XS series) from murine epidermis which retain important features of resident epidermal Langerhans cells (LC) are provided. These genes encode distinct type II membrane-integrated polypeptides, each consisting of a cytoplasmic domain, a transmembrane domain, an extracellular connecting domain, and a C-terminal extracellular domain that exhibits significant homology to the carbohydrate recognition domains (CRD) of C-type lectins. Expression of both genes is highly restricted to cells of DC lineage (including epidermal LC). Thus, these genes encode new, DC-specific members of the C-type lectin family, now termed "DC-associated C-type lectin-1 and -2" (dectin-1 and dectin-2). Two isoforms of the dectin-1 molecule and five isoforms of the dectin-2 molecule have also been identified. The invention further provides His-tagged fusion proteins comprising 6.times. histidine and the extracellular domain of dectin-1 or dectin-2. Also provided are antibodies raised to synthetic peptides designed from the dectin-1 sequence or to the His-tagged fusion proteins described.

L10 ANSWER 30 OF 65 USPATFULL

ACCESSION NUMBER: 2000:28143 USPATFULL
 TITLE: Azole compounds, their production and use
 INVENTOR(S): Itoh, Katsumi, Osaka, Japan
 Okonogi, Kenji, Osaka, Japan
 Tasaka, Akihiro, Osaka, Japan
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6034248		20000307
	WO 9625410		19960820
APPLICATION INFO.:	US 1996-624649		19961017 (8)
	WO 1996-JP325		19960215
			19961017 PCT 371 date
			19961017 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-29579	19950217
	JP 1995-285318	19951101
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Morris, Patricia L.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2340	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:28143 USPATFULL
 TI Azole compounds, their production and use
 IN Itoh, Katsumi, Osaka, Japan
 Okonogi, Kenji, Osaka, Japan
 Tasaka, Akihiro, Osaka, Japan
 PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
 PI US 6034248 20000307
 WO 9625410 19960820
 AI US 1996-624649 19961017 (8)
 WO 1996-JP325 19960215
 19961017 PCT 371 date
 19961017 PCT 102(e) date
 PRAI JP 1995-29579 19950217
 JP 1995-285318 19951101
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Morris, Patricia L.

LREP Foley & Lardner
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2340

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an azole compound represented by the formula (I): ##STR1## wherein Ar is an optionally substituted phenyl group; R.sup.1 and R.sup.2, the same or different, are a hydrogen atom or a lower alkyl group, or R.sup.1 and R.sup.2 may combine together to form a lower alkylene group; R.sup.3 is a hydrogen atom or an acyl group; X is a nitrogen atom or a methine group; A is Y.dbd.Z (Y and Z, the same or different, are a nitrogen atom or a methine group optionally substituted with a lower alkyl group) or an ethylene group optionally substituted with a lower alkyl group; n is an integer from 0 to 2; and Az is an optionally substituted azolyl group, or its salt, which is useful for a prevention and therapy of a fungal infection of a mammal as a antifungal agent.

L10 ANSWER 31 OF 65 USPATFULL

ACCESSION NUMBER: 2000:15506 USPATFULL
TITLE: Methods for the isolation of bacteria containing eukaryotic genes
INVENTOR(S): Robinson, Douglas H., 2301 N St., NW., Apt. 507, Washington, DC, United States 20037

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6022730		20000208
APPLICATION INFO.:	US 1996-719367		19960925 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-261977, filed on 17 Jun 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Eisenschenk, Chris		
ASSISTANT EXAMINER:	Zeman, Manyk		
LEGAL REPRESENTATIVE:	Rothwell, Figg, Ernst & Kurz, p.c.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	947		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:15506 USPATFULL
TI Methods for the isolation of bacteria containing eukaryotic genes
IN Robinson, Douglas H., 2301 N St., NW., Apt. 507, Washington, DC, United States 20037
PI US 6022730 20000208
AI US 1996-719367 19960925 (8)
RLI Continuation-in-part of Ser. No. US 1994-261977, filed on 17 Jun 1994
DT Utility
FS Granted
EXNAM Primary Examiner: Eisenschenk, Chris; Assistant Examiner: Zeman, Manyk
LREP Rothwell, Figg, Ernst & Kurz, p.c.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 947

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Bacteria containing eukaryotic and/or viral genes, and often having highly pleiomorphic morphology, are obtained by culturing virally-infected eukaryotic cells under aseptic, low oxygen conditions. The bacteria so produced express products encoded by the eukaryotic genes. Analyses indicate that several isolates obtained from culturing retrovirally-infected human brain capillary endothelial cells express human-specific genes previously mapped to widely separated human

chromosomes.

L10 ANSWER 32 OF 65 USPATFULL

ACCESSION NUMBER: 2000:1692 USPATFULL

TITLE: Sequence-directed DNA binding molecules compositions and methods

INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States

Cantor, Charles R., Boston, MA, United States

Andrews, Beth M., Maynard, MA, United States

Turin, Lisa M., Redwood City, CA, United States

Fry, Kirk E., Palo Alto, CA, United States

PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 6010849	20000104
---------------------	------------	----------

APPLICATION INFO.:	US 1995-482080	19950607 (8)
--------------------	----------------	--------------

RELATED APPLN. INFO.:	Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned	
-----------------------	--	--

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Degen, Nancy

ASSISTANT EXAMINER: Schwartzman, Robert

LEGAL REPRESENTATIVE: Fabin, Gary R. Dehlinger & Associates

NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 48 Drawing Figure(s); 47 Drawing Page(s)

LINE COUNT: 10022

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:1692 USPATFULL

TI Sequence-directed DNA binding molecules compositions and methods

IN Edwards, Cynthia A., Menlo Park, CA, United States

Cantor, Charles R., Boston, MA, United States

Andrews, Beth M., Maynard, MA, United States

Turin, Lisa M., Redwood City, CA, United States

Fry, Kirk E., Palo Alto, CA, United States

PA Genelabs Technologies, Inc., Redwood, CA, United States (U.S. corporation)

PI US 6010849 20000104

AI US 1995-482080 19950607 (8)

RLI Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Degen, Nancy; Assistant Examiner: Schwartzman, Robert

LREP Fabin, Gary R. Dehlinger & Associates

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 48 Drawing Figure(s); 47 Drawing Page(s)

LN.CNT 10022

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines a DNA:protein-binding assay useful for

screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 33 OF 65 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:216943 CAPLUS

DOCUMENT NUMBER: 130:236482

TITLE: Monoclonal antibody to T-cell-derived antigen-binding molecule (TABM) and detection of TABM in disease states

INVENTOR(S): Cone, Robert Edward; Georgiou, George Michael; Little, Colin Hughes

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 155 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9914243	A1	19990325	WO 1998-AU765	19980916
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9890558	A1	19990405	AU 1998-90558	19980916
PRIORITY APPLN. INFO.:			US 1997-59047P	P 19970916
			AU 1998-5850	A 19980911
			WO 1998-AU765	W 19980916

AN 1999:216943 CAPLUS

DN 130:236482

TI Monoclonal antibody to T-cell-derived antigen-binding molecule (TABM) and detection of TABM in disease states

IN Cone, Robert Edward; Georgiou, George Michael; Little, Colin Hughes

PA USA

SO PCT Int. Appl., 155 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9914243	A1	19990325	WO 1998-AU765	19980916
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,			

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9890558 A1 19990405 AU 1998-90558 19980916
PRAI US 1997-59047P P 19970916
AU 1998-5850 A 19980911
WO 1998-AU765 W 19980916

AB The present invention relates generally to immunointeractive mols. and their in the detection and/or purifn. of T-cell antigen binding mols. (TABMs). In a specific example, the authors disclose the prepn. and characterization of a monoclonal antibody to TABM. In a second example, transforming growth factor-.beta. is shown to bind TABM and to be activated on TABM binding to its cognate antigen. The ability to det. the presence and levels of particular TABMs may provide useful diagnostic procedures for a variety of disease conditions.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 34 OF 65 USPATFULL

ACCESSION NUMBER: 1999:155894 USPATFULL

TITLE: Anti-IgE antibodies and methods of improving polypeptides

INVENTOR(S): Lowman, Henry B., El Granada, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Jardieu, Paula M., San Mateo, CA, United States
Lowe, John, Daly City, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994511		19991130
APPLICATION INFO.:	US 1997-887352		19970702 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Saunders, David		
LEGAL REPRESENTATIVE:	Svoboda, Craig G.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 19 Drawing Page(s)		
LINE COUNT:	5816		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1999:155894 USPATFULL

TI Anti-IgE antibodies and methods of improving polypeptides

IN Lowman, Henry B., El Granada, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Jardieu, Paula M., San Mateo, CA, United States
Lowe, John, Daly City, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 5994511 19991130

AI US 1997-887352 19970702 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Saunders, David

LREP Svoboda, Craig G.

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 21 Drawing Figure(s); 19 Drawing Page(s)

LN.CNT 5816

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including:
(1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and

screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

L10 ANSWER 35 OF 65 USPATFULL

ACCESSION NUMBER: 1999:18912 USPATFULL

TITLE: Method of determining DNA sequence preference of a DNA-binding molecule

INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States

PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869241		19990209
APPLICATION INFO.:	US 1995-475228		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Zitomer, Stephanie W.		
ASSISTANT EXAMINER:	Whisenant, Ethan		
LEGAL REPRESENTATIVE:	Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	72 Drawing Figure(s); 47 Drawing Page(s)		
LINE COUNT:	9840		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1999:18912 USPATFULL

TI Method of determining DNA sequence preference of a DNA-binding molecule

IN Edwards, Cynthia A., Menlo Park, CA, United States

Cantor, Charles R., Boston, MA, United States

Andrews, Beth M., Maynard, MA, United States

Turin, Lisa M., Redwood City, CA, United States

Fry, Kirk E., Palo Alto, CA, United States

PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

PI US 5869241 19990209

AI US 1995-475228 19950607 (8)

RLI Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Whisenant,

Ethan
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 72 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 9840

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 36 OF 65 USPATFULL

ACCESSION NUMBER: 1998:159736 USPATFULL
TITLE: Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
INVENTOR(S): Better, Marc D., Los Angeles, CA, United States
PATENT ASSIGNEE(S): Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5851802		19981222
APPLICATION INFO.:	US 1996-621803		19960322 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spector, Lorraine		
LEGAL REPRESENTATIVE:	McAndrews, Held & Malloy, Ltd.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	4280		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:159736 USPATFULL
TI Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
IN Better, Marc D., Los Angeles, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5851802 19981222
AI US 1996-621803 19960322 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Spector, Lorraine
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 4280

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).

L10 ANSWER 37 OF 65 USPATFULL

ACCESSION NUMBER: 1998:124655 USPATFULL
TITLE: Method for making heteromultimeric polypeptides
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genetech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5821333		19981013
APPLICATION INFO.:	US 1995-434869		19950503 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-399106, filed on 1 Mar 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hutzell, Paula K.		
ASSISTANT EXAMINER:	Bakalyar, Heather A.		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	2573		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:124655 USPATFULL
TI Method for making heteromultimeric polypeptides
IN Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PA Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5821333 19981013
AI US 1995-434869 19950503 (8)
RLI Division of Ser. No. US 1995-399106, filed on 1 Mar 1995
DT Utility
FS Granted
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Bakalyar, Heather A.
LREP Lee, Wendy M.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2573

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. "Protuberances" are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis.

L10 ANSWER 38 OF 65 USPATFULL

ACCESSION NUMBER: 1998:111793 USPATFULL

TITLE: Method for making heteromultimeric polypeptides
 INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
 Presta, Leonard G., San Francisco, CA, United States
 Ridgway, John B., San Francisco, CA, United States
 PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5807706		19980915
APPLICATION INFO.:	US 1995-433105		19950503 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-399106, filed on 1 Mar 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hutzell, Paula K.		
ASSISTANT EXAMINER:	Bakalyar, Heather A.		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	2576		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:111793 USPTFULL
 TI Method for making heteromultimeric polypeptides
 IN Carter, Paul J., San Francisco, CA, United States
 Presta, Leonard G., San Francisco, CA, United States
 Ridgway, John B., San Francisco, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 5807706 19980915
 AI US 1995-433105 19950503 (8)
 RLI Division of Ser. No. US 1995-399106, filed on 1 Mar 1995
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Bakalyar, Heather A.
 LREP Lee, Wendy M.
 CLMN Number of Claims: 26
 ECL Exemplary Claim: 1
 DRWN 21 Drawing Figure(s); 11 Drawing Page(s)
 LN.CNT 2576

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. "Protuberances" are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis.

L10 ANSWER 39 OF 65 USPTFULL

ACCESSION NUMBER: 1998:44877 USPTFULL

TITLE: Sequence-directed DNA-binding molecules compositions and methods

INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5744131		19980428
APPLICATION INFO.:	US 1995-476876		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Zitomer, Stephanie W.		
ASSISTANT EXAMINER:	Atzel, Amy		
LEGAL REPRESENTATIVE:	Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 33 Drawing Page(s)		
LINE COUNT:	5113		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:44877 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5744131 19980428
AI US 1995-476876 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 5113

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L10 ANSWER 40 OF 65 USPATFULL
ACCESSION NUMBER: 1998:39383 USPATFULL

TITLE: Sequence-directed DNA-binding molecules compositions and methods

INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States

PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5738990		19980414
APPLICATION INFO.:	US 1995-475221		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Guzo, David		
ASSISTANT EXAMINER:	Brusca, John S.		
LEGAL REPRESENTATIVE:	Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 33 Drawing Page(s)		
LINE COUNT:	5040		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:39383 USPATFULL

TI Sequence-directed DNA-binding molecules compositions and methods

IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States

PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

PI US 5738990 19980414

AI US 1995-475221 19950607 (8)

RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Guzo, David; Assistant Examiner: Brusca, John S.

LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 48 Drawing Figure(s); 33 Drawing Page(s)

LN.CNT 5040

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L10 ANSWER 41 OF 65 USPATFULL

ACCESSION NUMBER: 1998:30879 USPATFULL
TITLE: Method for making heteromultimeric polypeptides
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5731168		19980324
APPLICATION INFO.:	US 1995-399106		19950301 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hutzell, Paula K.		
ASSISTANT EXAMINER:	Bakalyar, Heather A.		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	41		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	2657		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:30879 USPATFULL
TI Method for making heteromultimeric polypeptides
IN Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5731168 19980324
AI US 1995-399106 19950301 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Bakalyar,
Heather A.
LREP Lee, Wendy M.
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2657

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. "Protuberances" are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis.

L10 ANSWER 42 OF 65 USPATFULL

ACCESSION NUMBER: 1998:25075 USPATFULL
TITLE: Screening assay for the detection of DNA-binding molecules
INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States

PATENT ASSIGNEE(S): Cantor, Charles R., Boston, MA, United States
 Andrews, Beth M., Watertown, MA, United States
 Turin, Lisa M., Berkeley, CA, United States
 Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5726014		19980310
APPLICATION INFO.:	US 1993-123936		19930917 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jones, W. Gary		
ASSISTANT EXAMINER:	Atzel, Amy		
LEGAL REPRESENTATIVE:	Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	72 Drawing Figure(s); 47 Drawing Page(s)		
LINE COUNT:	5659		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:25075 USPATFULL
 TI Screening assay for the detection of DNA-binding molecules
 IN Edwards, Cynthia A., Menlo Park, CA, United States
 Cantor, Charles R., Boston, MA, United States
 Andrews, Beth M., Watertown, MA, United States
 Turin, Lisa M., Berkeley, CA, United States
 PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
 PI US 5726014 19980310
 AI US 1993-123936 19930917 (8)
 RLI Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Atzel, Amy
 LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
 CLMN Number of Claims: 19
 ECL Exemplary Claim: 1
 DRWN 72 Drawing Figure(s); 47 Drawing Page(s)
 LN.CNT 5659

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 43 OF 65 USPATFULL
 ACCESSION NUMBER: 1998:14634 USPATFULL
 TITLE: Method of constructing sequence-specific DNA-binding molecules

INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States
 Fry, Kirk E., Palo Alto, CA, United States
 Cantor, Charles R., Boston, MA, United States
 Andrews, Beth M., Watertown, MA, United States
 PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5716780		19980210
APPLICATION INFO.:	US 1995-484499		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jones, W. Gary		
ASSISTANT EXAMINER:	Atzel, Amy		
LEGAL REPRESENTATIVE:	Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 33 Drawing Page(s)		
LINE COUNT:	4929		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:14634 USPATFULL
 TI Method of constructing sequence-specific DNA-binding molecules
 IN Edwards, Cynthia A., Menlo Park, CA, United States
 Fry, Kirk E., Palo Alto, CA, United States
 Cantor, Charles R., Boston, MA, United States
 Andrews, Beth M., Watertown, MA, United States
 PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
 PI US 5716780 19980210
 AI US 1995-484499 19950607 (8)
 RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Atzel, Amy
 LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1
 DRWN 48 Drawing Figure(s); 33 Drawing Page(s)
 LN.CNT 4929

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L10 ANSWER 44 OF 65 USPATFULL
 ACCESSION NUMBER: 97:112300 USPATFULL

TITLE: Method of ordering sequence binding preferences of a DNA-binding molecule

INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States(4)

PATENT ASSIGNEE(S): Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5693463		19971202
APPLICATION INFO.:	US 1992-996783		19921223 (7)
DISCLAIMER DATE:	20110426		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Zitomer, Stephanie W.		
ASSISTANT EXAMINER:	Atzel, Amy		
LEGAL REPRESENTATIVE:	Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 33 Drawing Page(s)		
LINE COUNT:	4908		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 97:112300 USPATFULL

TI Method of ordering sequence binding preferences of a DNA-binding molecule

IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States(4)

PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

PI US 5693463 19971202

AI US 1992-996783 19921223 (7)

DCD 20110426

RLI Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Atzel, Amy

LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN 48 Drawing Figure(s); 33 Drawing Page(s)

LN.CNT 4908

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L10 ANSWER 45 OF 65 USPATFULL

ACCESSION NUMBER: 97:86278 USPATFULL
TITLE: Preservatives and their use
INVENTOR(S): Eggensperger, Heinz, Hamburg, Germany, Federal Republic
of
Diehl, Karl-Heinz, Norderstedt, Germany, Federal
Republic of
Oltmanns, Peter, Hamburg, Germany, Federal Republic of
PATENT ASSIGNEE(S): Schulke & Mayr GmbH, Hamburg, Germany, Federal Republic
of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5670160		19970923
APPLICATION INFO.:	US 1996-649254		19960130 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-115298, filed on 1 Sep 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-741008, filed on 6 Aug 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1990-4026756	19900824
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Marquis, Melvyn I.	
ASSISTANT EXAMINER:	Harrison, Robert H.	
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	782	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 97:86278 USPATFULL
TI Preservatives and their use
IN Eggensperger, Heinz, Hamburg, Germany, Federal Republic of
Diehl, Karl-Heinz, Norderstedt, Germany, Federal Republic of
Oltmanns, Peter, Hamburg, Germany, Federal Republic of
PA Schulke & Mayr GmbH, Hamburg, Germany, Federal Republic of (non-U.S.
corporation)
PI US 5670160 19970923
AI US 1996-649254 19960130 (8)
RLI Continuation of Ser. No. US 1993-115298, filed on 1 Sep 1993, now
abandoned which is a continuation-in-part of Ser. No. US 1991-741008,
filed on 6 Aug 1991, now abandoned
PRAI DE 1990-4026756 19900824
DT Utility
FS Granted
EXNAM Primary Examiner: Marquis, Melvyn I.; Assistant Examiner: Harrison,
Robert H.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 782

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A preservative, for compositions having an aqueous phase, comprising

a) 5 to 60% by weight of an organic acid selected from the group
consisting of benzoic acid, 4-hydroxybenzoic acid, salicylic acid,
formic acid, acetic acid, propionic acid, sorbic acid, undecylenic acid
and dehydracetic acid or their mixtures including their sodium,
potassium, calcium, magnesium, ammonium and ethanolamine salts

b) 10 to 95% by weight of alcohols of the general formulae I, II or III ##STR1## in which R.sub.1 denotes hydrogen, an n-alkyl, iso-alkyl or alkoxy radical having 1 to 3 C atoms, and R.sub.2 and R.sub.3 denote hydrogen or a CH.sub.3 -- or C.sub.2 H.sub.5 -- radical and n has the value of 3 or 4, and

c) 0.1 to 20% by weight of one or more poly(hexamethylenebiguanide) salts of the general formula ##STR2## in which Z represents hydrochloride, acetate, lactate, benzoate, propionate, 4-hydroxybenzoate, sorbate or salicylate; and n has the value of 4 to 6, in combination in a customary carrier or solvent.

L10 ANSWER 46 OF 65 USPATFULL

ACCESSION NUMBER: 97:51865 USPATFULL

TITLE: Method for detecting polynucleotides with immobilized polynucleotide probes identified based on T.sub.m

INVENTOR(S): Mitsuhashi, Masato, Irvine, CA, United States

Cooper, Allan, Bellview, WA, United States

PATENT ASSIGNEE(S): Hitachi Chemical Company, Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5639612		19970617
APPLICATION INFO.:	US 1995-379078		19950126 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-974406, filed on 12 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-922522, filed on 28 Jul 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Horlick, Kenneth R.		
LEGAL REPRESENTATIVE:	Knobbe, Martens, Olson & Bear		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	65 Drawing Figure(s); 63 Drawing Page(s)		
LINE COUNT:	5724		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 97:51865 USPATFULL

TI Method for detecting polynucleotides with immobilized polynucleotide probes identified based on T.sub.m

IN Mitsuhashi, Masato, Irvine, CA, United States

Cooper, Allan, Bellview, WA, United States

PA Hitachi Chemical Company, Ltd., Tokyo, Japan (non-U.S. corporation)

PI US 5639612 19970617

AI US 1995-379078 19950126 (8)

RLI Continuation of Ser. No. US 1992-974406, filed on 12 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-922522, filed on 28 Jul 1992, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Horlick, Kenneth R.

LREP Knobbe, Martens, Olson & Bear

CLMN Number of Claims: 37

ECL Exemplary Claim: 1

DRWN 65 Drawing Figure(s); 63 Drawing Page(s)

LN.CNT 5724

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for detecting the presence of a particular organism, infectious agent, or biological component of a cell or organism in a sample, based on sandwich hybridization in which first and second probes are used, and the specificity of the first probe is determined based on its melting temperature (T.sub.m) with the target polynucleotide at a selected sodium and formamide concentration.

L10 ANSWER 47 OF 65 USPATFULL

ACCESSION NUMBER: 97:36345 USPATFULL

TITLE: Esters of acyl L-carnitines and pharmaceutical compositions containing same for treating endotoxic shock

INVENTOR(S): Foresta, Piero, Pomezia, Italy
Ruggiero, Vito, Rome, Italy
Tinti, Maria O., Rome, Italy

PATENT ASSIGNEE(S): Scafetta, Nazareno, Pavona di Albano, Italy
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Rome, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5625085		19970429
APPLICATION INFO.:	US 1994-274686		19940714 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1993-RM468	19930714
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shippen, Michael L.	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 14 Drawing Page(s)	
LINE COUNT:	1019	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 97:36345 USPATFULL

TI Esters of acyl L-carnitines and pharmaceutical compositions containing same for treating endotoxic shock

IN Foresta, Piero, Pomezia, Italy
Ruggiero, Vito, Rome, Italy
Tinti, Maria O., Rome, Italy
Scafetta, Nazareno, Pavona di Albano, Italy

PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Rome, Italy (non-U.S. corporation)

PI US 5625085 19970429

AI US 1994-274686 19940714 (8)

PRAI IT 1993-RM468 19930714

DT Utility

FS Granted

EXNAM Primary Examiner: Shippen, Michael L.

LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN 14 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 1019

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters of alkanoyl L-carnitines wherein the alkanoyl is a saturated or unsaturated, straight or branched alkanoyl having 2-26 carbon atoms, optionally .omega.-substituted with trialkylammonium, dialkylsulfonium, hydroxyl, carboxyl, halogen, methanesulfonyl and hydroxysulfonyl, are useful for preparing pharmaceutical compositions for the treatment of endotoxic shock.

L10 ANSWER 48 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)

ACCESSION NUMBER: 97:368347 SCISEARCH

THE GENUINE ARTICLE: WX501

TITLE: Inhibition of human neutrophil functions by sulfated and nonsulfated cholecystokinin octapeptides

AUTHOR: Carrasco M; DelRio M; Hernanz A; DelaFuente M (Reprint)

CORPORATE SOURCE: UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN (Reprint); UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRAS, TAMIL NADU, INDIA
COUNTRY OF AUTHOR: SPAIN; INDIA
SOURCE: PEPTIDES, (APR 1997) Vol. 18, No. 3, pp. 415-422.
Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB.
ISSN: 0196-9781.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: English.
REFERENCE COUNT: 54

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 97:368347 SCISEARCH
GA The Genuine Article (R) Number: WX501
TI Inhibition of human neutrophil functions by sulfated and nonsulfated cholecystokinin octapeptides
AU Carrasco M; DelRio M; Hernanz A; DelaFuente M (Reprint)
CS UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN (Reprint); UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, MADRID, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRAS, TAMIL NADU, INDIA
CYA SPAIN; INDIA
SO PEPTIDES, (APR 1997) Vol. 18, No. 3, pp. 415-422.
Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB.
ISSN: 0196-9781.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 54
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB The effects of CCK-8s and desulfated CCK-8 at concentrations ranging from 10^{-14} to 10^{-6} M were studied in vitro on several functions of human peripheral neutrophils: adherence to substrate, mobility (spontaneous and directed by a chemical gradient or chemotaxis), ingestion of inert particles (latex beads) or cells (*Candida albicans*), and production of superoxide anion measured by the nitroblue tetrazolium reduction test. The effect of CCK-8s on intracellular levels of cAMP was investigated as well as the implication of calcium in the action of CCK-8s on phagocytic function using stimulants and inhibitors of both intracellular and extracellular calcium channels. The two peptides, at concentrations from 10^{-12} to 10^{-8} M, inhibited significantly both mobility and ingestion capacities and increased adherence to substrate. A dose-response relationship was observed with a maximum inhibition of neutrophil functions at 10^{-10} M. CCK-8s and desulfated CCK-8 induced in these cells a significant, but transient, increase of cAMP levels at 60 s. Moreover, CCK-8s was found to inhibit completely the stimulation of latex bead phagocytosis in neutrophils produced by the calcium ionophore A23187. These results suggest that CCK-8 is a negative modulator of several neutrophil functions and that the inhibition of these activities could be carried out through an increase of the intracellular cAMP levels and a decrease of the extracellular calcium input. (C) 1997 Elsevier Science Inc.

L10 ANSWER 49 OF 65 USPATFULL
ACCESSION NUMBER: 96:108816 USPATFULL
TITLE: Sequence-directed DNA-binding molecules compositions and methods
INVENTOR(S): Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States

PATENT ASSIGNEE(S): Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5578444		19961126
APPLICATION INFO.:	US 1993-171389		19931220 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Zitomer, Stephanie W.		
ASSISTANT EXAMINER:	Atzel, Amy		
LEGAL REPRESENTATIVE:	Fabian, Gary R., Brookes, Allen A., Stratford, Carol A.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	71 Drawing Figure(s); 48 Drawing Page(s)		
LINE COUNT:	5845		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 96:108816 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5578444 19961126
AI US 1993-171389 19931220 (8)
RLI Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Brookes, Allen A., Stratford, Carol A.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 71 Drawing Figure(s); 48 Drawing Page(s)
LN.CNT 5845

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 50 OF 65 USPATFULL
ACCESSION NUMBER: 96:38884 USPATFULL

TITLE: Immunological activity of rhamnolipids
INVENTOR(S): Piljac, Goran, 2323 Shasta Dr., Apt 40, Davis, CA,
United States 95616
Piljac, Visnja, 2323 Shasta Dr., Apt 40, Davis, CA,
United States 95616

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5514661		19960507
APPLICATION INFO.:	US 1995-520076		19950828 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-277975, filed on 20 Feb 1994, now patented, Pat. No. US 5466675 which is a continuation-in-part of Ser. No. US 1992-866691, filed on 10 Apr 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Griffin, Ronald W.		
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1424		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 96:38884 USPATFULL
TI Immunological activity of rhamnolipids
IN Piljac, Goran, 2323 Shasta Dr., Apt 40, Davis, CA, United States 95616
Piljac, Visnja, 2323 Shasta Dr., Apt 40, Davis, CA, United States 95616
PI US 5514661 19960507
AI US 1995-520076 19950828 (8)
RLI Division of Ser. No. US 1994-277975, filed on 20 Feb 1994, now patented, Pat. No. US 5466675 which is a continuation-in-part of Ser. No. US 1992-866691, filed on 10 Apr 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Griffin, Ronald W.
LREP Oblon, Spivak, McClelland, Maier & Neustadt
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1424

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating various autoimmune diseases and for providing immunorestitution, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;

R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;

R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl and

R.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl; are provided.

L10 ANSWER 51 OF 65 USPATFULL

ACCESSION NUMBER: 95:101209 USPATFULL

TITLE: Immunological activity of rhamnolipids

INVENTOR(S): Piljac, Goran, 2323 Shasta Dr., Apt. 40, Davis, CA,
United States 95616
Piljac, Visnja, 2323 Shasta Dr., Apt. 40, Davis, CA,
United States 95616

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5466675 19951114
APPLICATION INFO.: US 1994-277975 19940720 (8)
DISCLAIMER DATE: 20090410
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-866691, filed
on 10 Apr 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	BE 1992-115	19920204
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Griffin, Ronald W.	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1443	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 95:101209 USPATFULL
TI Immunological activity of rhamnolipids
IN Piljac, Goran, 2323 Shasta Dr., Apt. 40, Davis, CA, United States 95616
Piljac, Visnja, 2323 Shasta Dr., Apt. 40, Davis, CA, United States
95616
PI US 5466675 19951114
AI US 1994-277975 19940720 (8)
DCD 20090410
RLI Continuation-in-part of Ser. No. US 1992-866691, filed on 10 Apr 1992,
now abandoned
PRAI BE 1992-115 19920204
DT Utility
FS Granted
EXNAM Primary Examiner: Griffin, Ronald W.
LREP Oblon, Spivak, McClelland, Maier & Neustadt
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1443

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating various autoimmune diseases and for providing
immunorestitution, by administering, to a subject in need thereof, an
effective amount of a composition having, as active ingredient, one or
more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or
.alpha.-L-rhamnopyranosyl;

R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;

R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated
hydrocarbyl and

R.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated
hydrocarbyl;

are provided.

L10 ANSWER 52 OF 65 USPATFULL
ACCESSION NUMBER: 95:82344 USPATFULL
TITLE: Prolyl endopeptidase inhibitors SNA-115 and SNA-115T,
and process for the production and productive strain
thereof
INVENTOR(S): Kimura, Kenichi, Tochigi, Japan
Kanou, Fumiko, Tochigi, Japan
Takahashi, Hidetoshi, Tochigi, Japan
Kurosawa, Kazuhiko, Tochigi, Japan
Yoshihama, Makoto, Tochigi, Japan
PATENT ASSIGNEE(S): Snow Brand Milk Products Co., Ltd., Hokkaido, Japan

(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5449750		19950912
	WO 9300361		19930701
APPLICATION INFO.:	US 1993-977444		19930217 (7)
	WO 1992-JP784		19920619
			19930217 PCT 371 date
			19930217 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1991-176228	19910620
	JP 1992-78262	19920228
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Warden, Jill	
ASSISTANT EXAMINER:	Wessendorf, T. D.	
LEGAL REPRESENTATIVE:	Burgess, Ryan & Wayne	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	641	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 95:82344 USPATFULL

TI Prolyl endopeptidase inhibitors SNA-115 and SNA-115T, and process for the production and productive strain thereof

IN Kimura, Kenichi, Tochigi, Japan
Kanou, Fumiko, Tochigi, Japan
Takahashi, Hidetoshi, Tochigi, Japan
Kurosawa, Kazuhiko, Tochigi, Japan
Yoshihama, Makoto, Tochigi, Japan

PA Snow Brand Milk Products Co., Ltd., Hokkaido, Japan (non-U.S. corporation)

PI US 5449750 19950912
WO 9300361 19930701

AI US 1993-977444 19930217 (7)
WO 1992-JP784 19920619
19930217 PCT 371 date
19930217 PCT 102(e) date

PRAI JP 1991-176228 19910620
JP 1992-78262 19920228

DT Utility

FS Granted

EXNAM Primary Examiner: Warden, Jill; Assistant Examiner: Wessendorf, T. D.

LREP Burgess, Ryan & Wayne

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 10 Drawing Figure(s); 10 Drawing Page(s)

LN.CNT 641

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Prolyl endopeptidase inhibiting compounds SNA-115 and SNA-115T are provided having molecular formulas of C.sub.113 H.sub.142 N.sub.26 O.sub.27 and C.sub.113 H.sub.144 N.sub.26 O.sub.28 respectively. SNA-115T has the following structural formula:

Arg Tyr Asp Trp Trp Pro Tyr Gly Asp Leu Phe Gly Gly His Thr Phe Ile Ser
Pro

Processes are also provided for the production of SNA-11 by culturing the SNA productive microorganism and production of SNA-115T by degradation of SNA-115 with trypsin. Both SNA-115 and SNA-115T exhibit prolyl endopeptidase inhibitory properties.

L10 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:237581 CAPLUS

DOCUMENT NUMBER: 120:237581

TITLE: Detection of genes by nucleic acid hybridization using capture and reporter probes and optional nucleic acid amplification

INVENTOR(S): Mitsuhashi, Masato; Cooper, Allan

PATENT ASSIGNEE(S): Hitachi Chemical Company Ltd., Japan

SOURCE: PCT Int. Appl., 182 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9402636	A1	19940203	WO 1993-US999	19930129
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 652971	A1	19950517	EP 1993-905793	19930129
R: CH, DE, FR, GB, IT, LI				
JP 07509361	T2	19951019	JP 1993-504409	19930129
US 5580971	A	19961203	US 1995-379081	19950126
US 5639612	A	19970617	US 1995-379078	19950126
PRIORITY APPLN. INFO.:			US 1992-922522	19920728
			US 1992-974406	19921112
			WO 1993-US999	19930129

AN 1994:237581 CAPLUS

DN 120:237581

TI Detection of genes by nucleic acid hybridization using capture and reporter probes and optional nucleic acid amplification

IN Mitsuhashi, Masato; Cooper, Allan

PA Hitachi Chemical Company Ltd., Japan

SO PCT Int. Appl., 182 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9402636	A1	19940203	WO 1993-US999	19930129
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 652971	A1	19950517	EP 1993-905793	19930129
R: CH, DE, FR, GB, IT, LI				
JP 07509361	T2	19951019	JP 1993-504409	19930129
US 5580971	A	19961203	US 1995-379081	19950126
US 5639612	A	19970617	US 1995-379078	19950126
PRAI US 1992-922522		19920728		
US 1992-974406		19921112		
WO 1993-US999		19930129		

AB A method for detecting the presence of a particular organism, infectious agent, or component of a cell or organism in a biol. sample by nucleic acid hybridization is described. A hybridization probe for the target sequence is immobilized on a solid support, such as microtiter well, and the target sequence is then hybridized to the immobilized probe. A second, labeled probe is then hybridized to this support-polynucleotide structure and binding of this probe is used to quantify the target sequence. Sensitivity of the system may be improved by amplification of the bound or free target polynucleotide. Also included in the present invention are polynucleotide probes and primers and the use of an H-site model and algorithm for the design of these probes and primers with an .

optimized matching of Tm's based upon related sequences available in data banks.

L10 ANSWER 54 OF 65 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 95024893 EMBASE

DOCUMENT NUMBER: 1995024893

TITLE: High levels of IgA in HIV-1-perinatally-infected children: Antigen specificity and possible role of increased **substance P** plasma levels.

AUTHOR: Rossi M.E.; Resti M.; Azzari C.; Calabri G.; De Martino M.; Galli L.; Carbonella R.; Vierucci A.

CORPORATE SOURCE: Dipartimento di Pediatria, Via Luca Giordano 13,50132 Firenze, Italy

SOURCE: Pediatric Allergy and Immunology, (1994) 5/4 (240-243). ISSN: 0905-6157 CODEN: PALUEE

COUNTRY: Denmark

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 004 Microbiology
007 Pediatrics and Pediatric Surgery
026 Immunology, Serology and Transplantation

LANGUAGE: English

SUMMARY LANGUAGE: English

AN 95024893 EMBASE

DN 1995024893

TI High levels of IgA in HIV-1-perinatally-infected children: Antigen specificity and possible role of increased **substance P** plasma levels.

AU Rossi M.E.; Resti M.; Azzari C.; Calabri G.; De Martino M.; Galli L.; Carbonella R.; Vierucci A.

CS Dipartimento di Pediatria, Via Luca Giordano 13,50132 Firenze, Italy

SO Pediatric Allergy and Immunology, (1994) 5/4 (240-243).

ISSN: 0905-6157 CODEN: PALUEE

CY Denmark

DT Journal; Article

FS 004 Microbiology
007 Pediatrics and Pediatric Surgery
026 Immunology, Serology and Transplantation

LA English

SL English

AB The specificity of IgA against food, inhalant, bacterial and fungine antigens as well as for HIV-1 proteins was investigated in 14 HIV-1-infected children (CDC stage P-2) and 15 controls. IgA against food- and inhalant antigens as well as against tetanus toxoid were significantly more often present in the HIV positive children than in controls. No difference between the two groups was present for IgA against **Candida albicans**. A significant increase of **substance P**, a strong IgA synthesis inducing neuropeptide, was demonstrated in the plasma of HIV-1 infected children. In conclusion, high levels of IgA seem to reflect a complex immune dysfunction in which many factors are involved. The importance of neuroimmune dysregulation is discussed.

L10 ANSWER 55 OF 65 USPATFULL

ACCESSION NUMBER: 93:74284 USPATFULL

TITLE: Defensin peptide compositions and methods for their use

INVENTOR(S): Murphy, Christopher J., Davis, CA, United States

Reid, Ted W., Davis, CA, United States

Mannis, Mark J., Carmichael, CA, United States

Foster, Bradley A., Davis, CA, United States

Cullor, James S., Woodland, CA, United States

Selsted, Michael E., Los Angeles, CA, United States

Lehrer, Robert I., Santa Monica, CA, United States

Ganz, Tomas, Los Angeles, CA, United States

PATENT ASSIGNEE(S): The Regents of the University of California, Oakland,

CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5242902		19930907
APPLICATION INFO.:	US 1989-404249		19890906 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Griffin, Ronald W.		
LEGAL REPRESENTATIVE:	Townsend and Townsend Khourie and Crew		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	702		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 93:74284 USPTFULL
TI Defensin peptide compositions and methods for their use
IN Murphy, Christopher J., Davis, CA, United States
Reid, Ted W., Davis, CA, United States
Mannis, Mark J., Carmichael, CA, United States
Foster, Bradley A., Davis, CA, United States
Cullor, James S., Woodland, CA, United States
Selsted, Michael E., Los Angeles, CA, United States
Lehrer, Robert I., Santa Monica, CA, United States
Ganz, Tomas, Los Angeles, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 5242902 19930907
AI US 1989-404249 19890906 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Griffin, Ronald W.
LREP Townsend and Townsend Khourie and Crew
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 702

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating cutaneous and corneal wounds as well as certain microbial-related diseases comprises topically applying a defensin peptide to the affected tissue. The compositions comprise a natural, synthetic, or analog defensin molecule having both a mitogenic activity capable of stimulating cell growth and an antimicrobial activity capable of inhibiting the growth of a wide variety of pathogens. In addition to therapeutic use, the defensins are useful as mitogens in cell and tissue culture media.

L10 ANSWER 56 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)

ACCESSION NUMBER: 93:689339 SCISEARCH

THE GENUINE ARTICLE: MF885

TITLE: STIMULATION BY VASOACTIVE-INTESTINAL-PEPTIDE (VIP) OF PHAGOCYTIC FUNCTION IN RAT MACROPHAGES - PROTEIN-KINASE-C INVOLVEMENT

AUTHOR: DELAFUENTE M (Reprint); DELGADO M; DELRIO M; MARTINEZ C; HERNANZ A; GOMARIZ R P

CORPORATE SOURCE: UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT FISIOL ANIM, MADRID 3, SPAIN; UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL CELULAR, MADRID 3, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRID, SPAIN

COUNTRY OF AUTHOR: SPAIN

SOURCE: REGULATORY PEPTIDES, (03 NOV 1993) Vol. 48, No. 3, pp. 345-353.

ISSN: 0167-0115.

DOCUMENT TYPE: Article; Journal

FILE SEGMENT: LIFE
LANGUAGE: ENGLISH
REFERENCE COUNT: 44

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 93:689339 SCISEARCH
GA The Genuine Article (R) Number: MF885
TI STIMULATION BY VASOACTIVE-INTESTINAL-PEPTIDE (VIP) OF PHAGOCYTTIC FUNCTION
IN RAT MACROPHAGES - PROTEIN-KINASE-C INVOLVEMENT
AU DELAFUENTE M (Reprint); DELGADO M; DELRIO M; MARTINEZ C; HERNANZ A;
GOMARIZ R P
CS UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT FISIOL ANIM, MADRID 3,
SPAIN; UNIV COMPLUTENSE MADRID, FAC CIENCIAS BIOL, DEPT BIOL CELULAR,
MADRID 3, SPAIN; HOSP LA PAZ, SERV BIOQUIM, MADRID, SPAIN
CYA SPAIN
SO REGULATORY PEPTIDES, (03 NOV 1993) Vol. 48, No. 3, pp. 345-353.
ISSN: 0167-0115.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 44

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The action of vasoactive intestinal peptide (VIP) on macrophages has not yet been studied, although there are studies that show an inhibitory action of VIP on lymphocyte functions. The present study shows that VIP in a range from $10(-12)$ to $10(-7)$ M increased significantly the phagocytosis and digestion capacities of rat peritoneal macrophages. The most effective concentration of VIP was $10(-9)$ M followed by $10(-8)$ M. With respect to the phagocytic capacity, the ingestion of cells (**Candida albicans**) or inert particles (latex beads) was stimulated significantly with all the concentrations used. The digestion capacity was analyzed through the production of superoxide anion, measured by the reduction of nitroblue tetrazolium (NBT). As with phagocytic capacity, superoxide anion production was increased by VIP in non-stimulated macrophages (incubated without latex beads) and even more in stimulated cells (incubated in the presence of latex beads). The study of the mechanism of action of this neuropeptide showed that protein kinase C (PKC) was activated in the presence of VIP concentrations from $10(-10)$ to $10(-8)$ M in a similar way to that found with a specific PKC activator such as phorbol myristate acetate (PMA, 50 ng/ml). PMA also stimulated significantly the phagocytosis and digestion capacities of rat macrophages. By contrast, a PKC inhibitor, retinal (20 μ M), decreased significantly the phagocytosis and digestion capacities. These data show that VIP could stimulate these macrophage functions through PKC activation.

L10 ANSWER 57 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)

ACCESSION NUMBER: 93:606596 SCISEARCH

THE GENUINE ARTICLE: LZ829

TITLE: STIMULATION OF MURINE PERITONEAL MACROPHAGE FUNCTIONS BY
NEUROPEPTIDE-Y AND PEPTIDE YY - INVOLVEMENT OF
PROTEIN-KINASE-C

AUTHOR: DELAFUENTE M (Reprint); BERNAEZ I; DELRIO M; HERNANZ A
CORPORATE SOURCE: UNIV COMPLUTENSE, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL
ANIM 2, E-28040 MADRID, SPAIN (Reprint); HOSP LA PAZ
INSALUD, SERV BIOQUIM, MADRID, SPAIN

COUNTRY OF AUTHOR: SPAIN

SOURCE: IMMUNOLOGY, (OCT 1993) Vol. 80, No. 2, pp. 259-265.
ISSN: 0019-2805.

DOCUMENT TYPE: Article; Journal

FILE SEGMENT: LIFE

LANGUAGE: ENGLISH

REFERENCE COUNT: 38

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 93:606596 SCISEARCH

GA The Genuine Article (R) Number: LZ829
TI STIMULATION OF MURINE PERITONEAL MACROPHAGE FUNCTIONS BY NEUROPEPTIDE-Y
AND PEPTIDE YY - INVOLVEMENT OF PROTEIN-KINASE-C
AU DELAFUENTE M (Reprint); BERNAEZ I; DELRIO M; HERNANZ A
CS UNIV COMPLUTENSE, FAC CIENCIAS BIOL, DEPT BIOL ANIM FISIOL ANIM 2, E-28040
MADRID, SPAIN (Reprint); HOSP LA PAZ INSALUD, SERV BIOQUIM, MADRID, SPAIN
CYA SPAIN
SO IMMUNOLOGY, (OCT 1993) Vol. 80, No. 2, pp. 259-265.
ISSN: 0019-2805.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 38

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The peptides neuropeptide Y (NPY) and peptide YY (PYY) at concentrations from 10(-12) M to 10(-8) M have been shown in this study to stimulate significantly, in vitro, several functions of resting peritoneal macrophages from BALB/c mice: adherence to substrate, chemotaxis, ingestion of inert particles (latex beads) and foreign cells (*Candida albicans*), and production of superoxide anion measured by nitroblue tetrazolium reduction. A dose-response relationship was observed, with a maximal stimulation of the macrophage functions studied at 10(-10) M. These effects seem to be produced by specific receptors for the neuropeptides studied in peritoneal macrophages. Whereas the two peptides induced no change of intracellular cyclic AMP, they caused a significant stimulation of protein kinase C (PKC) in murine macrophages. These results suggest that NPY and PYY produce their effects on macrophage function through PKC activation.

L10 ANSWER 58 OF 65 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1993:500498 BIOSIS

DOCUMENT NUMBER: PREV199396124505

TITLE: Inhibition of murine intestinal inflammation by anti-**substance P** antibody.

AUTHOR(S): Agro, Albert; Stanis, Andrzej M. (1)

CORPORATE SOURCE: (1) Intestinal Dis. Res. Prog., Dep. Pathol., McMaster Univ., 1200 Main St. West, Hamilton, ON L8N 3Z5 Canada
SOURCE: Regional Immunology, (1993) Vol. 5, No. 2, pp. 120-126.
ISSN: 0896-0623.

DOCUMENT TYPE: Article

LANGUAGE: English

AN 1993:500498 BIOSIS

DN PREV199396124505

TI Inhibition of murine intestinal inflammation by anti-**substance P** antibody.

AU Agro, Albert; Stanis, Andrzej M. (1)

CS (1) Intestinal Dis. Res. Prog., Dep. Pathol., McMaster Univ., 1200 Main St. West, Hamilton, ON L8N 3Z5 Canada

SO Regional Immunology, (1993) Vol. 5, No. 2, pp. 120-126.
ISSN: 0896-0623.

DT Article

LA English

AB Several neuropeptides have recently been shown to affect various aspects of the inflammatory process. Among these, the neuropeptide **substance P** possesses a host of immune modifying actions, which include the enhancement of lymphocyte activity, macrophage function, and neutrophil chemotaxis. The role of **substance P** during inflamed states has, as yet, not been fully described. Here, in T. spiralis-infected mice, we parallel increased levels of **substance P** both locally, (the gut) and peripherally (serum) with decreased lymphocyte responsiveness. Upon the introduction of in vivo antisubstance P antibody during the infection, levels of **substance P**, gastrointestinal inflammation, and lymphocyte proliferation are significantly restored to baseline (noninfected) levels. These findings

suggest that the neuropeptide **substance P** plays an important role in promoting inflammation. It also offers the basis for future pharmacological interventions.

L10 ANSWER 59 OF 65 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 91:430018 SCISEARCH
THE GENUINE ARTICLE: FY390
TITLE: RETENTION OF AMPHOTERICIN-B THERAPEUTIC EFFICACY AT HALF
DOSES BY SYNERGISTIC ACTIVATION OF PHAGOCYTES
AUTHOR: CORNAGLIAFERRARIS P (Reprint); ROSSI E; PEREZZANI L;
STRADI R
CORPORATE SOURCE: GASLINI CHILDRENS HOSP, PEDIAT ONCOL RES LAB, L GO G
GASLINI 5, I-16148 GENOA, ITALY (Reprint)
COUNTRY OF AUTHOR: ITALY
SOURCE: CANCER DETECTION AND PREVENTION, (1991) Vol. 15, No. 4,
pp. 327-329.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: CLIN
LANGUAGE: ENGLISH
REFERENCE COUNT: No References Keyed

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 91:430018 SCISEARCH
GA The Genuine Article (R) Number: FY390
TI RETENTION OF AMPHOTERICIN-B THERAPEUTIC EFFICACY AT HALF DOSES BY
SYNERGISTIC ACTIVATION OF PHAGOCYTES
AU CORNAGLIAFERRARIS P (Reprint); ROSSI E; PEREZZANI L; STRADI R
CS GASLINI CHILDRENS HOSP, PEDIAT ONCOL RES LAB, L GO G GASLINI 5, I-16148
GENOA, ITALY (Reprint)
CYA ITALY
SO CANCER DETECTION AND PREVENTION, (1991) Vol. 15, No. 4, pp. 327-329.
DT Article; Journal
FS CLIN
LA ENGLISH
REC No References Keyed

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Amphotericin B (AMB) is a mainstay in the treatment of serious systemic fungal infections, such as those occurring prevalently in immuno-compromised patients treated with immunosuppressive agents or affected by Acquired Immunodeficiency Syndrome (AIDS). However AMB is an extremely toxic agent whose therapeutical utilization is often accompanied by acute side effects and chronic impairment of renal function. It is here reported that the preactivation of polymorphonucleated cells (PMN) in vivo, by a new immunomodulatory agent (PCF 39:N alpha-5[1,6,dihydro-(6-oxo-9 purinyl) pentoxycarbonyl]-L-Arginine) allows marked reduction of the AMB doses with full retention of therapeutic efficacy. This was observed in an experimental fungal infection induced in mice by intravenous inoculation of **Candida albicans**.

L10 ANSWER 60 OF 65 USPATFULL
ACCESSION NUMBER: 87:20665 USPATFULL
TITLE: N-substituted diaminopropane/glutamic acid reaction
products
INVENTOR(S): Gerhardt, Werner, Hilden, Germany, Federal Republic of
Fischer, Herbert, Duesseldorf, Germany, Federal
Republic of
Lehmann, Rudolf, Leichlingen, Germany, Federal Republic
of
Disch, Karlheinz, Haan, Germany, Federal Republic of
Leinen, Hans T., Aachen, Germany, Federal Republic of
PATENT ASSIGNEE(S): Henkel Kommanditgesellschaft auf Aktien, Duesseldorf,
Germany, Federal Republic of (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 4652585 19870324
APPLICATION INFO.: US 1985-713126 19850315 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1984-3410956	19840324
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shippen, Michael L.	
LEGAL REPRESENTATIVE:	Szoke, Ernest G., Millson, Jr., Henry E., Greenfield, Mark A.	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1,16	
LINE COUNT:	700	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 87:20665 USPATFULL
TI N-substituted diaminopropane/glutamic acid reaction products
IN Gerhardt, Werner, Hilden, Germany, Federal Republic of
Fischer, Herbert, Duesseldorf, Germany, Federal Republic of
Lehmann, Rudolf, Leichlingen, Germany, Federal Republic of
Disch, Karlheinz, Haan, Germany, Federal Republic of
Leinen, Hans T., Aachen, Germany, Federal Republic of
PA Henkel Kommanditgesellschaft auf Aktien, Duesseldorf, Germany, Federal
Republic of (non-U.S. corporation)
PI US 4652585 19870324
AI US 1985-713126 19850315 (6)
PRAI DE 1984-3410956 19840324
DT Utility
FS Granted
EXNAM Primary Examiner: Shippen, Michael L.
LREP Szoke, Ernest G., Millson, Jr., Henry E., Greenfield, Mark A.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1,16
DRWN No Drawings
LN.CNT 700

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds which are the reaction products of a C.sub.12-14 -alkyl
N-substituted 1,3-diaminopropane and glutamic acid or its 5-methyl
ester, optionally alkoxylated, and optionally their salts, are useful as
antimicrobial agents.

L10 ANSWER 61 OF 65 CABA COPYRIGHT 2002 CABI

ACCESSION NUMBER: 88:14558 CABA
DOCUMENT NUMBER: 881340734
TITLE: Inhibitory effects of levamisole- and
tetramisole-hydrochloride (in vitro) on Prototheca
zopfii and **Candida albicans**
Hemmwirkung von Levamisol- und
Tetramisolhydrochlorid in vitro gegen Prototheca
zopfii und **Candida albicans**
AUTHOR: Bergmann, A.
CORPORATE SOURCE: Wissenschaftsbereich Microbiologie und Tierseuchen,
Sektion Tierproduktion und Veterinarmedizin der
Karl-Marx Universitat, Leipzig, German Democratic
Republic.
SOURCE: Monatshefte fur Veterinarmedizin, (1987) Vol. 42,
No. 16, pp. 599-602. 7 ref.
DOCUMENT TYPE: Journal
LANGUAGE: German
SUMMARY LANGUAGE: English; Russian

AN 88:14558 CABA

DN 881340734

TI Inhibitory effects of levamisole- and tetramisole-hydrochloride (in vitro)
on Prototheca zopfii and **Candida albicans**

Hemmwirkung von Levamisol- und Tetramisolhydrochlorid in vitro gegen
Prototheca zopfii und **Candida albicans**

AU Bergmann, A.
CS Wissenschaftsbereich Microbiologie und Tierseuchen, Sektion Tierproduction
und Veterinarmedizin der Karl-Marx Universitat, Leipzig, German Democratic
Republic.
SO Monatshefte fur Veterinarmedizin, (1987) Vol. 42, No. 16, pp. 599-602. 7
ref.
DT Journal
LA German
SL English; Russian
AB Agar gel and paper disc diffusion tests were performed on 5 *P. zopfii*
strs. obtained from cases of mastitis and 5 *C. albicans* strs.
obtained from pathological material from various animal species. Levamisol
hydrochloride was clearly shown to be the better of the 2 active
substances. *P. zopfii* proved to be more sensitive than
C. albicans. A comparison of the paper disc diffusion test with
antifungal agents used in human medicine revealed that 4 of 5 *P. zopfii*
strs. were more sensitive to tetramisol hydrochloride. Levamisol
hydrochloride was found to be superior to nystatin in its action against
C. albicans, but less so when compared with amphotericin B.
Miconazole showed no antifungal effect against all *P. zopfii* strs.

L10 ANSWER 62 OF 65 USPATFULL

ACCESSION NUMBER: 84:18660 USPATFULL

TITLE: Pharmaceutical composition comprising derivative of
aminobenzoic acid for regulating prostaglandin

INVENTOR(S): Yoshikumi, Chikao, Kunitachi, Japan
Ohmura, Yoshio, Funabashi, Japan
Hirose, Fumio, Tokyo, Japan
Ikuzawa, Masanori, Tachikawa, Japan
Matsunaga, Kenichi, Tokyo, Japan
Fujii, Takayoshi, Tokyo, Japan
Ohhara, Minoru, Tokyo, Japan
Ando, Takao, Tokyo, Japan

PATENT ASSIGNEE(S): Kureha Kagaku Kogyo Kabushiki Kaisha, Tokyo, Japan
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4440757		19840403
APPLICATION INFO.:	US 1980-174543		19800801 (6)
DISCLAIMER DATE:	19990202		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1979-84467, filed on 12 Oct 1979, now patented, Pat. No. US 4322409 And a continuation-in-part of Ser. No. US 1979-81190, filed on 10 Feb 1979, now patented, Pat. No. US 4322408 And a continuation-in-part of Ser. No. US 1979-102535, filed on 11 Dec 1979, now patented, Pat. No. US 4313939 And a continuation-in-part of Ser. No. US 1979-102224, filed on 10 Dec 1979, now patented, Pat. No. US 4315921 , said Ser. No. 84467		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-40594	19780406
	JP 1978-42014	19780410
	JP 1978-42015	19780410
	JP 1978-42576	19780411
	JP 1978-63146	19780526
	JP 1978-161385	19781229
	JP 1978-161386	19781229
	JP 1980-91113	19800705

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Hazel, Blondel
LEGAL REPRESENTATIVE: Wegner & Bretschneider
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1,5
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 1669

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 84:18660 USPATFULL
TI Pharmaceutical composition comprising derivative of aminobenzoic acid
for regulating prostaglandin
IN Yoshikumi, Chikao, Kunitachi, Japan
Ohmura, Yoshio, Funabashi, Japan
Hirose, Fumio, Tokyo, Japan
Ikuzawa, Masanori, Tachikawa, Japan
Matsunaga, Kenichi, Tokyo, Japan
Fujii, Takayoshi, Tokyo, Japan
Ohhara, Minoru, Tokyo, Japan
Ando, Takao, Tokyo, Japan
PA Kureha Kagaku Kogyo Kabushiki Kaisha, Tokyo, Japan (non-U.S.
corporation)
PI US 4440757 19840403
AI US 1980-174543 19800801 (6)
DCD 19990202
RLI Continuation-in-part of Ser. No. US 1979-84467, filed on 12 Oct 1979,
now patented, Pat. No. US 4322409 And a continuation-in-part of Ser. No.
US 1979-81190, filed on 10 Feb 1979, now patented, Pat. No. US 4322408
And a continuation-in-part of Ser. No. US 1979-102535, filed on 11 Dec
1979, now patented, Pat. No. US 4313939 And a continuation-in-part of
Ser. No. US 1979-102224, filed on 10 Dec 1979, now patented, Pat. No. US
4315921, said Ser. No. 84467
PRAI JP 1978-40594 19780406
JP 1978-42014 19780410
JP 1978-42015 19780410
JP 1978-42576 19780411
JP 1978-63146 19780526
JP 1978-161385 19781229
JP 1978-161386 19781229
JP 1980-91113 19800705
DT Utility
FS Granted
EXNAM Primary Examiner: Hazel, Blondel
LREP Wegner & Bretschneider
CLMN Number of Claims: 8
ECL Exemplary Claim: 1,5
DRWN 16 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1669

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition for regulating prostagrandins, which
comprises (a) a derivative of aminobenzoic acid, represented by the
following general formula: ##STR1## wherein R.sup.1 denotes one member
selected from the group consisting of the residual groups formed by
removing OH at 1(alpha)-or 1(beta) position from arabinose, xylose,
rhamnose, glucose, galactose, mannose and fructose, and R.sup.2 is a
hydrogen atom, an alkyl group of one to four carbon atoms or a
pharmaceutically acceptable metal, and (b) a pharmaceutically acceptable
carrier or diluent of (a) is disclosed.

L10 ANSWER 63 OF 65 USPATFULL

ACCESSION NUMBER: 78:45570 USPATFULL
TITLE: Method for preparing antibiotic P-2563 using
Pseudomonas fluorescens
INVENTOR(S): Nara, Kiyoshi, Kyoto, Japan
Sumino, Yasuhiro, Kobe, Japan

PATENT ASSIGNEE(S): Asai, Mitsuko, Takatsuki, Japan
Akiyama, Shunichi, Suita, Japan
Takeda Chemical Industries, Ltd., Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4108724		19780822
APPLICATION INFO.:	US 1976-674310		19760407 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1975-15062	19750411
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Jones, Raymond N.	
ASSISTANT EXAMINER:	Wiseman, Thomas G.	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	878	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 78:45570 USPATFULL
TI Method for preparing antibiotic P-2563 using Pseudomonas fluorescens
IN Nara, Kiyoshi, Kyoto, Japan
Sumino, Yasuhiro, Kobe, Japan
Asai, Mitsuko, Takatsuki, Japan
Akiyama, Shunichi, Suita, Japan
PA Takeda Chemical Industries, Ltd., Japan (non-U.S. corporation)
PI US 4108724 19780822
AI US 1976-674310 19760407 (5)
PRAI GB 1975-15062 19750411
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, Raymond N.; Assistant Examiner: Wiseman, Thomas G.
LREP Wenderoth, Lind & Ponack
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s).
LN.CNT 878

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel antibiotic P-2563 is produced by cultivating a microorganism of the genus Pseudomonas.

The antibiotic is useful as a drug for the treatment of pustule, and also useful as a disinfectant.

L10 ANSWER 64 OF 65 USPATFULL
ACCESSION NUMBER: 76:35182 USPATFULL
TITLE: Antimicrobial agents for water conservation
INVENTOR(S): Koppensteiner, Gunter, Hilden, Rhineland, Germany, Federal Republic of
Eckert, Hans-Werner, Dusseldorf, Germany, Federal Republic of
Wehle, Volker, Hilden, Rhineland, Germany, Federal Republic of
PATENT ASSIGNEE(S): Henkel & Cie G.m.b.H., Dusseldorf, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3965265		19760622

APPLICATION INFO.: US 1975-542229 19750120 (5)
RELATED APPLN. INFO.: Division of Ser. No. US 1973-352941, filed on 20 Apr
1973, now patented, Pat. No. US 3874869

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1972-2220026	19720424
	DE 1973-2314221	19730322
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ore, Dale R.	
LEGAL REPRESENTATIVE:	Hammond & Littell	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
LINE COUNT:	883	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 76:35182 USPATFULL
TI Antimicrobial agents for water conservation
IN Koppensteiner, Gunter, Hilden, Rhineland, Germany, Federal Republic of
Eckert, Hans-Werner, Dusseldorf, Germany, Federal Republic of
Wehle, Volker, Hilden, Rhineland, Germany, Federal Republic of
PA Henkel & Cie G.m.b.H., Dusseldorf, Germany, Federal Republic of
(non-U.S. corporation)
PI US 3965265 19760622
AI US 1975-542229 19750120 (5)
RLI Division of Ser. No. US 1973-352941, filed on 20 Apr 1973, now patented,
Pat. No. US 3874869
PRAI DE 1972-2220026 19720424
DE 1973-2314221 19730322
DT Utility
FS Granted
EXNAM Primary Examiner: Ore, Dale R.
LREP Hammond & Littell
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 883

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the prevention of the growth of microorganisms, especially
in industrial water, comprises contacting these microorganisms with an
effective antimicrobial amount of a reaction product of
.epsilon.-caprolactam and an N-alkylalkylene diamine with the reaction
being carried out in the liquid phase for 3 to 20 hours at a temperature
about 180.degree.C. The process further comprises incorporating into
said industrial water an effective amount of a sequestering agent
comprising a water-soluble phosphonic acid which forms a complex with a
divalent metal, a water-soluble salt of the acid and the mixtures
thereof, with the weight ratio of sequestering agent to reaction product
being 1:10 to 10:1.

L10 ANSWER 65 OF 65 USPATFULL

ACCESSION NUMBER: 75:16586 USPATFULL
TITLE: Antimicrobial agents for water conservation
INVENTOR(S): Koppensteiner, Gunter, Hilden, Rhineland, Germany,
Federal Republic of
Eckert, Hans-Werner, Dusseldorf, Germany, Federal
Republic of
Wehle, Volker, Hilden, Germany, Federal Republic of
PATENT ASSIGNEE(S): Henkel & Cie G.m.b.H., Dusseldorf, Germany, Federal
Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3874869		19750401

APPLICATION INFO.: US 1973-352941 19730420 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1972-2220026	19720424
	DE 1973-2314221	19730322
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Hollrah, Glennon H.	
LEGAL REPRESENTATIVE:	Hammond & Littell	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	797	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 75:16586 USPATFULL
TI Antimicrobial agents for water conservation
IN Koppensteiner, Gunter, Hilden, Rhineland, Germany, Federal Republic of
Eckert, Hans-Werner, Dusseldorf, Germany, Federal Republic of
Wehle, Volker, Hilden, Germany, Federal Republic of
PA Henkel & Cie G.m.b.H., Dusseldorf, Germany, Federal Republic of
(non-U.S. corporation)
PI US 3874869 19750401
AI US 1973-352941 19730420 (5)
PRAI DE 1972-2220026 19720424
DE 1973-2314221 19730322
DT Utility
FS Granted
EXNAM Primary Examiner: Hollrah, Glennon H.
LREP Hammond & Littell
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 797

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the prevention of the growth of microorganisms, especially in industrial water, comprises contacting these microorganisms with an effective antimicrobial amount of a reaction product of .epsilon.-caprolactam and an N-alkylalkylene diamine with the reaction being carried out in the liquid phase for 3 to 20 hours at a temperature above 180.degree.C. The process further comprises incorporating into said industrial water an effective amount of a sequestering agent comprising a water-soluble phosphonic acid which forms a complex with a divalent metal, a water-soluble salt of the acid and the mixtures thereof, with the weight ratio of sequestering agent to reaction product being 1:10 to 10:1.

=>

=>